Takeda Pharmaceutical Co Ltd
TAKHealthcare|Drug Manufacturers - Specialty & Generic|Japan
$16.56
-0.05 (-0.30%)
DCF (FCF)
$23.41
Clinical Trials (501)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT04809363 A Study of CDPATH™ to Help Manage and Treat Crohn's Disease | Crohn's Disease | P4 | Active | 200 | Open-label | — |
| NCT06180382 Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration. | Crohn's Disease | P4 | Recruiting | 220 | RCT, Open-label | Adalimumab, Vedolizumab |
| NCT05067868 A Study of Replagal in Children and Adults With Fabry Disease in India | Fabry Disease | P4 | Recruiting | 5 | Open-label | Replagal |
| NCT06581328 A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting | Ulcerative Colitis, Crohn's Disease | P4 | Recruiting | 400 | Open-label | Vedolizumab IV, Vedolizumab SC |
| NCT06562543 A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer | Colorectal Cancer | P4 | Recruiting | 78 | Open-label | Fruquintinib |
| NCT06045754 A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease | Crohn's Disease | P4 | Recruiting | 100 | Open-label | Vedolizumab, Adalimumab, Ustekinumab, Ustekinumab |
| NCT05156983 A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery | Coagulation Disorder | P3 | Recruiting | 440 | RCT, Double-blind | TAK-330, SOC 4F-PCC |
| NCT07129343 A Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants With Von Willebrand Disease (vWD) | Von Willebrand Disease (VWD) | P3 | Recruiting | 20 | Open-label | VONVENDI, ADVATE |
| NCT06439342 A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections | Cytomegalovirus (CMV) | P3 | Recruiting | 20 | Open-label | Maribavir |
| NCT07286058 Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis | Psoriatic Arthritis | P3 | Recruiting | 1,182 | RCT, Double-blind | Zasocitinib |
| NCT06227910 A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease | Crohn's Disease | P3 | Recruiting | 396 | RCT, Double-blind | Vedolizumab, Upadacitinib, Placebo |
| NCT06550076 A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis | Plaque Psoriasis | P3 | Active | 2,099 | Open-label | TAK-279 |
| NCT05899673 An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if Fazirsiran Can Help People With Alpha-1 Antitrypsin Liver Disease | Alpha1-Antitrypsin Deficiency | P3 | Active | 31 | Open-label | Fazirsiran Injection |
| NCT06671483 A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines | Psoriatic Arthritis | P3 | Recruiting | 1,088 | RCT, Double-blind | Zasocitinib, Active Comparator, Placebo |
| NCT03589326 A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) | P3 | Active | 245 | RCT, Open-label | Ponatinib, Imatinib, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone |
| NCT06405087 A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD) | Ulcerative Colitis, Crohn's Disease | P3 | Recruiting | 70 | RCT, Open-label | Vedolizumab SC |
| NCT05442567 A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD) | Ulcerative Colitis, Crohn's Disease | P3 | Recruiting | 240 | Open-label | Vedolizumab IV |
| NCT04563520 SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis | Hemophilia A | P3 | Recruiting | 5 | Open-label | Emicizumab, FEIBA, rFVIIa |
| NCT05677971 Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein | Alpha1-Antitrypsin Deficiency | P3 | Recruiting | 160 | RCT, Double-blind | Fazirsiran Injection |
| NCT07422480 A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions | Myelodysplastic Syndrome, Anemia | P3 | Recruiting | 300 | RCT, Open-label | Elritercept, Epoetin Alfa |
| NCT07363720 A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy | Narcolepsy Type 1 (NT1), Narcolepsy With Cataplexy | P3 | Recruiting | 88 | RCT, Double-blind | TAK-861, Placebo |
| NCT04129502 TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | P3 | Active | 354 | RCT, Open-label | TAK-788, Pemetrexed, Cisplatin, Carboplatin |
| NCT07205718 A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors | Advanced or Metastatic Solid Tumors | P1P2 | Recruiting | 223 | Open-label | TAK-188 |
| NCT03263572 Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia | P2 | Recruiting | 90 | Open-label | Blinatumomab, Cytarabine, Methotrexate, Ponatinib |
| NCT06233461 A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease | Crohn's Disease | P2 | Recruiting | 268 | RCT, Double-blind | TAK-279, Placebo |
| NCT04925609 Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors | Anaplastic Large Cell Lymphoma, ALK-Positive, Inflammatory Myofibroblastic Tumor | P1P2 | Recruiting | 65 | Open-label | Brigatinib |
| NCT04009109 Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM | Myeloma, Multiple | P2 | Active | 79 | RCT, Open-label | Lenalidomide, Ixazomib, Daratumumab Injection, Dexamethasone |
| NCT05020015 A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) | Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) | P2 | Active | 27 | Open-label | TAK-007, Chemotherapy Agents |
| NCT04419649 A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) | Myelodysplastic Syndromes, Cytopenia | P2 | Recruiting | 160 | Open-label | Elritercept |
| NCT07244263 A Study of Zasocitinib in Adults With Hidradenitis Suppurativa | Hidradenitis Suppurativa | P2 | Recruiting | 90 | RCT, Double-blind | Zasocitinib (Dose A) |
| NCT06798012 A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | P2 | Recruiting | 36 | Open-label | TAK-411 |
| NCT07011576 A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL) | Colon Cancer, Rectal Cancer | P2 | Recruiting | 60 | Open-label | fruquintinib, FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) |
| NCT07108283 A Study of Zasocitinib in Adults With Nonsegmental Vitiligo | Nonsegmental Vitiligo | P2 | Recruiting | 200 | RCT, Double-blind | Zasocitinib |
| NCT04464200 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers | Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma | P1 | Active | 30 | Open-label | 19(T2)28z1xx CAR T cells |
| NCT06856902 BEhavioral and Adherence Model for Improving Quality, Health Outcomes and Cost-Effectiveness of healthcaRe | Cardiovascular Diseases, Endocrinology | N/A | Recruiting | 3,100 | RCT, Open-label | — |
| NCT05879757 Real-world Usage of HyQvia in Multiple Myeloma Adults With Secondary Immunodeficiency | Multiple Myeloma, Secondary Immunodeficiency (SID) | Recruiting | 75 | — | — | |
| NCT05735327 A Study of Brigatinib as Preferred First Therapy for Adults With Non-Small Cell Lung Cancer (NSCLC) ENTIRETY | Non-small Cell Lung Cancer (NSCLC) | Active | 50 | — | No intervention | |
| NCT04838522 A Study of Prucalopride in Breastfeeding Women With Constipation | Chronic Idiopathic Constipation (CIC) | Recruiting | 12 | — | — | |
| NCT05626088 A Study in Adults With Inflammatory Bowel Disease (IBD) Receiving Vedolizumab in the Patient Support Program (PSP) in Brazil | Ulcerative Colitis, Crohn's Disease | Active | 1,006 | — | — | |
| NCT07293897 A Database Study of Maralixibat (TAK-625) in Participants With Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC) | Alagille Syndrome (ALGS), Progressive Familial Intrahepatic Cholestasis (PFIC) | Recruiting | 50 | — | Maralixibat | |
| NCT05100056 A Study of Brentuximab Vedotin in Adults With Hodgkin's Lymphoma | Hodgkin Lymphoma | Recruiting | 70 | — | — | |
| NCT07035886 A Study to Monitor the Fruzaqla Treatment of Adults With Metastatic Colorectal Cancer (mCRC) in South Korea | Colorectal Cancer | Recruiting | 600 | — | — | |
| NCT07123350 Evaluating the Shift From Intravenous to Subcutaneous Vedolizumab for Inflammatory Bowel Disease | Inflammatory Bowel Disease (IBD), Crohn&Amp;#39;s Disease (CD) | Active | 120 | — | Patient switched from IV vedolizumab to subcutaneous vedolizumab as part of normal patient care | |
| NCT06787105 Fruquintinib in Patients With Metastatic Colorectal Cancer | Metastatic Colorectal Cancer (mCRC) | Recruiting | 150 | — | — | |
| NCT06213974 A Study of Maribavir in Adults and Children With Post-transplant Cytomegalovirus (CMV) Infection in Argentina | Cytomegalovirus (CMV) | Recruiting | 10 | — | — | |
| NCT05158517 VeDOlizumab PERsistence in IBD Patients After Switching From Intravenous to Subcutaneous Administration : a Real-life Multicenter Study (DOPER) | Inflammatory Bowel Diseases | Active | 349 | — | Subcutaneous vedolizumab | |
| NCT05030493 An Additional Analysis of Data From the PARADIGM Exploratory Study (NCT02394834) in Patients With Advanced/Recurrent Colorectal Cancer | Colorectal Cancer | Active | 787 | — | mFOLFOX6 + panitumumab combination therapy, mFOLFOX6 + bevacizumab combination therapy | |
| NCT04158934 A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A | Hemophilia A | Active | 207 | — | ADYNOVI/ADYNOVATE | |
| NCT02394834 An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of mFOLFOX6 + Bevacizumab Versus mFOLFOX6 + Panitumumab Therapy in Patients With Chemotherapy-naïve Unresectable Advanced or Recurrent Colorectal Cancer | Colorectal Cancer | Active | 757 | — | oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab, oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab | |
| NCT05844033 Biomarker for Infection Risk in CLL and MM | Multiple Myeloma, Chronic Lymphocytic Leukemia | Active | 150 | — | — | |
| NCT07494058 A Study of Home vs Hospital Treatment in People With Fabry, Gaucher or Hunter Conditions in Mexico | Lysosomal Disease | Active | 222 | — | — | |
| NCT06590974 A Study of Freeze-dried Human Protein C Concentrate (TAK-662) in Participants With Congenital Protein C Deficiency | Protein C Deficiency | Recruiting | 7 | — | Freeze-dried Human Protein C Concentrate | |
| NCT07404644 An Observational Study of Vonicog Alfa (rVWF) in Pediatric Participants With Von Willebrand Disease (vWD) | Von Willebrand Disease (vWD) | Recruiting | 13 | — | vonicog alfa (rVWF) | |
| NCT01990040 Registry for Participants With Short Bowel Syndrome | Short Bowel Syndrome | Active | 1,806 | — | — | |
| NCT05469789 A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE) | Hereditary Angioedema (HAE) | Active | 50 | — | — | |
| NCT02646657 An Open Label Phase 4 Study to Evaluate Efficacy of Early Versus Late Use of Vedolizumab in Ulcerative Colitis | Colitis, Ulcerative | P4 | Completed | 120 | Open-label | Vedolizumab 300 mg |
| NCT00492011 Efficacy of Ramelteon on Insomnia Symptoms Associated With Jet Lag in Healthy Adult Volunteers | Circadian Dysregulation | P4 | Completed | 110 | RCT, Double-blind | Ramelteon, Ramelteon, Ramelteon, Placebo |
| NCT02763007 An Extension Study of PEAK Trial | Diabetes Mellitus, Type 2 | P4 | Terminated | 41 | RCT, Open-label | alogliptin+pioglitazone, alogliptin, pioglitazone |
| NCT00160121 Efficacy and Safety of Fosrenol in Treating Elevated Serum Phosphate Levels in Adults With End Stage Renal Disease | Kidney Failure, Chronic | P4 | Completed | 2,500 | Open-label | Lanthanum carbonate |
| NCT00816218 Molecular Mechanisms of Type 2 Diabetes Mellitus | Type 2 Diabetes Mellitus | P4 | Completed | 39 | RCT, Open-label | Pioglitazone |
| NCT00204373 Treatment of Zollinger-Ellison Syndrome With Prevacid | Zollinger-Ellison Syndrome, Multiple Endocrine Neoplasia | P4 | Completed | 72 | Open-label | Lansoprazole (Prevacid) |
| NCT00514813 Dynepo Long-Term Safety Study | Anemia, Kidney Failure, Chronic | P4 | Terminated | 152 | Open-label | Dynepo |
| NCT02517866 Azilsartan Medoxomil in the Treatment of Essential Hypertension and Type 2 Diabetes in Asia | Essential Hypertension, Type 2 Diabetes Mellitus | P4 | Completed | 380 | Open-label | Azilsartan Medoxomil |
| NCT02170402 China ADVATE PTP Study | Hemophilia A | P4 | Completed | 82 | Open-label | Octocog alfa (recombinant human coagulation factor VIII) |
| NCT02669082 The Exploratory Study to Investigate the Effect of Ramelteon for Insomnia Patients With Major Depressive Disorder by Using Actigraphy | Insomnia, Major Depressive Disorder | P4 | Completed | 26 | Open-label | Ramelteon |
| NCT00452478 Conversion From Standard Phosphate Binder Therapy to Fosrenol® (Lanthanum Carbonate) in Chronic Kidney Disease Stage 5 | Kidney Diseases | P4 | Terminated | 68 | Open-label | Lanthanum carbonate |
| NCT01518946 Tilt-Table Study of the Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension | Orthostatic Hypotension | P4 | Completed | 24 | RCT, Double-blind | Midodrine HCl, Placebo |
| NCT00770367 Pioglitazone and Serum Asymmetric Dimethylarginine (ADMA) in Patients With Diabetes | Diabetes | P4 | Completed | 36 | RCT, Double-blind | Pioglitazone then Placebo, Placebo then Pioglitazone |
| NCT02001857 Effect of TachoSil® on Incidence of Symptomatic and Radiographic Lymphoceles After Extended Pelvic Lymph Node Dissection in Prostate and Bladder Cancer. | Prostate or Bladder Cancer | P4 | Completed | 200 | RCT, Double-blind | 1 TachoSil hemostatic sponge (9,5 cm x 4,8 cm) placed on each side on the external iliac artery. |
| NCT01651351 GLASSIA Infusion Rate Study | Alpha1-antitrypsin Deficiency, Healthy Volunteers | P4 | Completed | 30 | RCT, Double-blind | Alpha1-proteinase inhibitor, Placebo: Human albumin 2.5% |
| NCT01328756 Lisdexamfetamine Dimesylate 2-year Safety Study in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD) | Attention Deficit Hyperactivity Disorder (ADHD) | P4 | Completed | 314 | Open-label | Lisdexamfetamine dimesylate |
| NCT02969876 Pattern Separation, Brain Derived Neurotrophic Factors, and Mechanisms of Vortioxetine | Depressive Disorder, Major Depression | P4 | Terminated | 2 | Open-label | Vortioxetine |
| NCT01224756 Efficacy of Tinoridine in Treating Pain and Inflammation in Adults | Pain, Inflammation | P4 | Completed | 342 | RCT, Double-blind | Tinoridine HCl, Placebo |
| NCT00525317 Does Oral Magnesium Substitution Relieve Pregnancy Induced Leg Cramps ? | Cramps | P4 | Completed | 45 | RCT, Double-blind | "Nycoplus Magnesium" (120 mg x 3 daily for 2 weeks) |
| NCT02427958 A Study to Assess the Safety and Efficacy of Leuprorelin in Central Precocious Puberty in Chinese Participants | Central Precocious Puberty | P4 | Completed | 307 | Open-label | Leuprorelin |
| NCT03079050 An Open-Label Trial of Dexlansoprazole 60mg for the Relief of Heartburn During the Fasting Month of Ramadan | GERD, Proton Pump Inhibitor | P4 | Completed | 33 | Open-label | Dexlansoprazole 60 MG |
| NCT03752606 Application of Tachosil During Lymphadenectomy | Lymphocele, Endometrial Cancer | P4 | Completed | 50 | RCT, Single-blind | TACHOSIL GROUP |
| NCT02824432 Exploratory Study of the Effect of Omega-3-acid Ethyl Esters (TAK-085) on Vascular Endothelial Function in Patients With Hyperlipidemia by Flow Mediated Dilation | Hyperlipidemia | P4 | Completed | 37 | RCT, Open-label | TAK-085 |
| NCT01763996 The Influence of Febuxostat on Coronary Artery Endothelial Dysfunction in Participants With Chronic Stable Angina | Coronary Artery Disease | P4 | Completed | 30 | RCT, Double-blind | Febuxostat, Febuxostat placebo |
| NCT01848210 Efficacy and Safety of Coumarin and Troxerutin in the Symptomatic Treatment of Chronic Venous Insufficiency | Chronic Venous Insufficiency | P4 | Completed | 829 | RCT, Double-blind | Coumarin/troxerutin, Placebo |
| NCT05183139 A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed/Refractory Multiple Myeloma | Multiple Myeloma | P4 | Withdrawn | — | Open-label | Ixazomib, Pomalidomide, Lenalidomide, Dexamethasone |
| NCT05414864 Insomnia Prevalence and Treatment Impact on Systemic Hypertension | Insomnia, Hypertension | P4 | Terminated | 5 | RCT, Open-label | Ramelteon (RozeremR) |
| NCT00916032 Pharmacokinetic Study of ADVATE 3000 IU in Previously Treated Patients With Severe Hemophilia A | Hemophilia A | P4 | Completed | 29 | RCT, Open-label | Octocog alfa (recombinant human coagulation factor VIII) [ADVATE] |
| NCT00246909 Determination of the Minimal Clinically Important Difference After Treatment With Pantoprazole in Patients With Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/M3-340) | Gastroesophageal Reflux | P4 | Completed | 600 | RCT, Double-blind | Pantoprazole |
| NCT02616315 Efficacy of Naltrexone HCl/Bupropion HCl Extended Release Versus Placebo for Treatment of Weight Regain in Participants Post Bariatric Surgery | Weight Regain Post Bariatric Surgery | P4 | Withdrawn | — | RCT, Double-blind | Naltrexone HCl/Bupropion HCl Placebo, Naltrexone HCl/Bupropion HCl |
| NCT00746395 Randomized, Placebo-controlled Trial of Lubiprostone as a Preparation for Capsule Endoscopy | Inflammatory Bowel Disease | P4 | Completed | 45 | RCT, Double-blind | Lubiprostone, Placebo |
| NCT00289536 Dose-Response Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A | Hemophilia A | P4 | Completed | 38 | RCT, Open-label | Antihemophilic factor, recombinant, manufactured protein-free, Antihemophilic factor, recombinant, manufactured protein-free, Antihemophilic factor, recombinant, manufactured protein-free |
| NCT01460225 Effects of Lubiprostone on Gastric Function in Patients With Chronic Idiopathic Constipation | Chronic Idiopathic Constipation | P4 | Completed | 19 | Open-label | lubiprostone |
| NCT00446849 Strategies in Maintenance for Patients Receiving Long-term Therapy (S.I.M.P.L.E.) With MMX (Multi-Matrix System) Mesalamine for Ulcerative Colitis (UC) | Ulcerative Colitis | P4 | Completed | 290 | Open-label | MMX Mesalamine |
| NCT00775814 Efficacy of Candesartan on Reducing Blood Pressure in Insulin-Resistant, Obese Patients With Hypertension. | Obesity, Hypertension | P4 | Completed | 188 | RCT, Double-blind | Candesartan and Hydrochlorothiazide, Hydrochlorothiazide (HCT) |
| NCT01101022 Safety and Efficacy of SPD489 on Executive Function Behaviors in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) | ADHD Specifically With Executive Function Impairment | P4 | Completed | 161 | RCT, Double-blind | SPD489 |
| NCT00953043 Lubiprostone, Colonic Motility and Sensation | Healthy | P4 | Completed | 60 | RCT, Double-blind | lubiprostone, Placebo |
| NCT00500071 Dose-Optimization Study Evaluating the Efficacy, Safety and Tolerability of Vyvanse (Lisdexamfetamine Dimesylate) in Children Aged 6-12 Diagnosed With ADHD | Attention Deficit Hyperactivity Disorder (ADHD) | P4 | Completed | 318 | Open-label | Vyvanse (lisdexamfetamine dimesylate) |
| NCT00046475 A Study for Patients With Neurogenic Orthostatic Hypotension | Hypotension, Orthostatic | P4 | Completed | 140 | RCT, Double-blind | Midodrine Hydrochloride |
| NCT01012479 Efficacy and Safety of Candesartan Cilexetil Plus Hydrochlorothiazide in Subjects With Severe Hypertension | Hypertension | P4 | Completed | 107 | Open-label | Candesartan cilexetil and hydrochlorothiazide |
| NCT00622427 Ramelteon for Treatment of Adult Patients With ADHD-Related Insomnia | ADHD With Sleep Onset Insomnia | P4 | Completed | 32 | RCT, Double-blind | Ramelteon, Placebo |
| NCT00151892 Efficacy and Safety of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis | Ulcerative Colitis | P3 | Completed | 829 | RCT, Double-blind | SPD476, Asacol |
| NCT01106430 Comparison of Lisdexamfetamine Dimesylate With Atomoxetine HCl in Attention-Deficit/Hyperactivity Disorder (ADHD) Subjects With an Inadequate Response to Methylphenidate | Attention-Deficit/Hyperactivity Disorder | P3 | Completed | 267 | RCT, Double-blind | Lisdexamfetamine Dimesylate, Atomoxetine Hydrochloride |
| NCT06470828 A Study of TAK-861 for the Treatment of Narcolepsy Type 1 | Narcolepsy Type 1 | P3 | Completed | 168 | RCT, Double-blind | TAK-861, Placebo |
| NCT00256178 Efficacy of Lapaquistat Acetate and Simvastatin in Subjects With Primary Dyslipidemia. | Hypercholesterolemia | P3 | Completed | 411 | RCT, Double-blind | Lapaquistat acetate and simvastatin, Lapaquistat acetate and simvastatin, Simvastatin |
| NCT00312806 Effect of Pantoprazole on the Symptoms of Acid Reflux Disease in Adult Patients (BY1023/M3-341) | Gastroesophageal Reflux Disease (GERD) | P3 | Completed | 2,000 | Open-label | Pantoprazole |
| NCT00175032 A Comparison of Safety and Treatment in Subjects With Osteoarthritis Taking Low Dose Aspirin | Osteoarthritis, Peptic Ulcer | P3 | Completed | 1,045 | RCT, Double-blind | Lansoprazole and naproxen and aspirin, Celecoxib and aspirin |
| NCT01890122 Efficacy and Safety of Alogliptin and Metformin Fixed-Dose Combination in Participants With Type 2 Diabetes | Diabetes Mellitus | P3 | Completed | 647 | RCT, Double-blind | Alogliptin, Metformin HCl, Alogliptin and Metformin Fixed-Dose Combination (FDC), Alogliptin Placebo, Metformin Placebo, Alogliptin and Metformin FDC Placebo |
| NCT00500656 Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema (HAE) | Hereditary Angioedema | P3 | Completed | 85 | RCT, Double-blind | Icatibant, Tranexamic Acid, Oral Placebo, S.C. Placebo |
| NCT00247390 Long-Term Efficacy and Safety of Ramelteon in Adults With Chronic Insomnia. | Chronic Insomnia | P3 | Completed | 451 | RCT, Double-blind | Ramelteon, Placebo |
| NCT03004924 Treatment of Bacterial Conjunctivitis With SHP640 Compared to PVP-Iodine and Placebo | Bacterial Conjunctivitis | P3 | Completed | 753 | RCT, Double-blind | SHP640, PVP-I 0.6%, Placebo |
| NCT00432276 Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus | Diabetes Mellitus | P3 | Completed | 803 | RCT, Double-blind | Alogliptin, Pioglitazone, Metformin, Placebo |
| NCT00306384 Long-term Safety of Alogliptin in Patients With Type 2 Diabetes Mellitus | Diabetes Mellitus | P3 | Completed | 3,323 | RCT, Open-label | Alogliptin |
| NCT00462709 Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks | Hereditary Angioedema | P3 | Completed | 146 | Open-label | C1 esterase inhibitor [human] (C1INH-nf) |
| NCT01122121 Leuprorelin Associated With Radiotherapy Versus Leuprorelin Alone in T3 - T4 or pT3 (on Biopsy) N0, M0 Prostate Cancer | Prostatic Neoplasms, Locally Advanced | P3 | Completed | 273 | RCT, Open-label | Leuprorelin SR, Flutamide |
| NCT00251745 Efficacy and Safety of Dexlansoprazole Modified Release Formulation to Treat Heartburn | Gastroesophageal Reflux Disease | P3 | Completed | 908 | RCT, Double-blind | Dexlansoprazole MR, Dexlansoprazole MR, Placebo |
| NCT00161096 On-Demand Use of Pantoprazole: Determinants for Chronic Use of Acid Suppressive Medication | Chronic Use of Acid Suppressive Medication, GORD | P3 | Unknown | 276 | RCT, Double-blind | pantoprazole 20 mg (drug) |
| NCT01436162 Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder | Major Depressive Disorder | P3 | Completed | 1,105 | RCT, Double-blind | Antidepressant + SPD489 (Lisdexamfetamine dimesylate ), Antidepressant + Placebo |
| NCT01760993 Long-term Safety of SPD489 When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia | Schizophrenia | P3 | Terminated | 2 | Open-label | SPD489 |
| NCT02072330 Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536CCB and Hydrochlorothiazide in Patients With Grade I or II Essential Hypertension. | Grade I or II Essential Hypertension | P2P3 | Completed | 353 | RCT, Double-blind | TAK-536CCB, TAK-536CCB + Hydrochlorothiazide, Hydrochlorothiazide, Hydrochlorothiazide, TAK-536CCB + Hydrochlorothiazide |
| NCT01521962 Study of Combination Therapy With SYR-322 | Diabetes Mellitus | P3 | Completed | 67 | RCT | Alogliptin, Insulin |
| NCT00656994 Long-Term Efficacy of Ramelteon on Endocrine Function in Adult Subjects With Chronic Insomnia | Insomnia | P3 | Completed | 122 | RCT, Double-blind | Ramelteon, Placebo |
| NCT01850524 IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma | Multiple Myeloma | P3 | Completed | 705 | RCT, Double-blind | Ixazomib, Placebo, Dexamethasone, Lenalidomide |
| NCT00220961 Actos Now for Prevention of Diabetes (ACT NOW) | Impaired Glucose Tolerance, Type 2 Diabetes | P3 | Completed | 602 | RCT, Double-blind | Pioglitazone, Placebo |
| NCT03999996 Long-Term Safety and Antibody Persistence of TDV and the Impact of a Booster Dose | Dengue Fever | P3 | Completed | 365 | RCT, Double-blind | Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV), Placebo |
| NCT00696384 A Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension | Hypertension | P3 | Completed | 418 | RCT, Double-blind | Azilsartan medoxomil, Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications., Placebo |
| NCT03259308 Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis | Ulcerative Colitis | P3 | Terminated | 279 | RCT, Double-blind | Ontamalimab, Placebo |
| NCT03364738 Safety and Efficacy Study of rhPTH(1-84) in Subjects With Hypoparathyroidism | Hypoparathyroidism | P3 | Terminated | 22 | Open-label | rhPTH(1-84) |
| NCT06108544 A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period | Plaque Psoriasis | P3 | Completed | 1,108 | RCT, Double-blind | TAK-279, Placebo, Apremilast |
| NCT00143663 Effect of Lapaquistat Acetate on Blood Cholesterol Levels in Subjects With Elevated Cholesterol | Dyslipidemia | P3 | Completed | 361 | RCT, Double-blind | Lapaquistat Acetate, Placebo |
| NCT01481116 Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes | Diabetes Mellitus, Type 2 | P3 | Terminated | 2,454 | RCT, Double-blind | TAK-875, TAK-875, Glimepiride |
| NCT04840667 A Study of Replagal in Treatment-naïve Adults With Fabry Disease | Fabry Disease | P3 | Terminated | 17 | Open-label | REPLAGAL |
| NCT01459367 Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Maintenance Treatment of Healed Erosive Esophagitis | Erosive Esophagitis | P3 | Completed | 607 | RCT, Double-blind | TAK-438, TAK-438, Lansoprazole |
| NCT02620046 A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease | Colitis, Ulcerative, Crohn's Disease | P3 | Completed | 746 | Open-label | Vedolizumab SC |
| NCT00268697 Efficacy of Lapaquistat Acetate Alone and With Ezetimibe in Subjects With Primary Dyslipidemia. | Hypercholesterolemia | P3 | Completed | 1,267 | RCT, Double-blind | Lapaquistat acetate, Lapaquistat acetate and ezetimibe, Ezetimibe |
| NCT03627091 Efficacy and Safety Study of Ontamalimab as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307) | Crohn's Disease | P3 | Terminated | 40 | RCT, Double-blind | Ontamalimab |
| NCT02037477 Phase 3 Study to Evaluate the Acid-Inhibitory Effect of Multiple Oral Doses of Vonoprazan (TAK-438) | Healthy Volunteers | P3 | Completed | 20 | RCT, Open-label | Vonoprazan, Esomeprazole, Rabeprazole sodium |
| NCT03050307 Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Gastric Ulcer Participants With or Without Helicobacter Pylori Infection | Gastric Ulcer | P3 | Completed | 234 | RCT, Double-blind | TAK-438, Lansoprazole, TAK-438 Placebo, Lansoprazole Placebo, Bismuth-Containing Quadruple Therapy |
| NCT02655237 A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids | Uterine Fibroids | P3 | Completed | 281 | RCT, Double-blind | Relugolix, Relugolix Placebo, Leuprorelin, Leuprorelin Placebo |
| NCT01842841 Multicenter Extension Study of Velaglucerase Alfa in Japanese Patients With Gaucher Disease | Gaucher Disease | P3 | Completed | 5 | Open-label | velaglucerase alfa |
| NCT00762957 Safety and Efficacy of TAK-559 in Combination With Metformin in Patients With Type 2 Diabetes Mellitus. | Diabetes Mellitus | P3 | Terminated | 15 | RCT, Double-blind | TAK-559 and metformin, TAK-559 and metformin, Metformin |
| NCT00868127 Safety of Lapaquistat Acetate in Subjects With Hypercholesterolemia | Hypercholesterolemia | P3 | Completed | 574 | Open-label | Lapaquistat acetate, Lapaquistat acetate and additional lipid-lowering therapy |
| NCT00671086 Efficacy of Ramelteon in Subjects With Chronic Insomnia | Sleep Initiation and Maintenance Disorders | P3 | Completed | 1,213 | Open-label | Ramelteon, Ramelteon |
| NCT00818662 A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease | Alzheimer´s Disease | P3 | Completed | 390 | RCT, Double-blind | Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg, Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 200 mg/kg, Placebo solution: Human Albumin 0.25% - 4 mL/kg, Placebo solution: Human Albumin 0.25% - 2 mL/kg |
| NCT00324974 The Use of Lansoprazole to Treat Infants With Symptoms of Gastroesophageal Reflux | Gastroesophageal Reflux Disease | P3 | Completed | 162 | RCT, Double-blind | Lansoprazole microgranules suspension, Placebo |
| NCT00430625 A Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Gaucher Disease | Gaucher Disease, Type 1 | P3 | Completed | 25 | RCT, Double-blind | VPRIV ®, |
| NCT02949362 Long-term Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome Who Completed the TED-C13-003 Study | Short Bowel Syndrome | P3 | Completed | 29 | Open-label | Teduglutide |
| NCT01609582 Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease | Type 2 Diabetes, Cardiovascular Disease | P3 | Terminated | 3,207 | RCT, Double-blind | TAK-875, TAK-875 Placebo |
| NCT01564537 A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma | Relapsed Multiple Myeloma, Refractory Multiple Myeloma | P3 | Completed | 722 | RCT, Double-blind | Ixazomib, Lenalidomide, Dexamethasone, Placebo |
| NCT00864851 Safety and Efficacy Study of Several Replagal Dosing Regimens on Cardiac Function in Adults With Fabry Disease | Fabry Disease | P3 | Completed | 44 | RCT, Open-label | Replagal |
| NCT02954159 Vedolizumab Monotherapy Vs Combination Therapy With Tacrolimus in UC | Ulcerative Colitis | P3 | Terminated | 4 | RCT, Double-blind | Tacrolimus, Vedolizumab |
| NCT01048242 Treatment of Insomnia in Elderly Sleep Apnea Patients With Ramelteon (TAK 375) | Insomnia, Obstructive Sleep Apnea | P3 | Completed | 27 | RCT, Double-blind | rozerem, Placebo |
| NCT00152035 Safety of SPD465 in Treating Adults With ADHD. | Attention Deficit Disorder With Hyperactivity | P3 | Completed | 505 | Open-label | Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate. |
| NCT01582854 Efficacy and Safety of Actovegin in Post-stroke Cognitive Impairment (PSCI) | Post-Stroke Cognitive Impairment (PSCI) | P3 | Completed | 503 | RCT, Double-blind | Actovegin, Placebo |
| NCT00671294 Safety and Efficacy of Ramelteon in Elderly Subjects With Chronic Insomnia. | Chronic Insomnia | P3 | Completed | 100 | RCT, Double-blind | Ramelteon and Placebo (9 possible combinations total) |
| NCT02283268 Recombinant Von Willebrand Factor in Subjects With Severe Von Willebrand Disease Undergoing Surgery | Von Willebrand Disease | P3 | Completed | 24 | Open-label | Recombinant von Willebrand Factor (rVWF) |
| NCT02276274 Effect of Food on the Pharmacokinetics of Single Oral Dose Administration of a Fixed-Dose Combination of SYR-322 and Metformin Hydrochloride in Healthy Adult Male Subjects | Clinical Pharmacology | P3 | Completed | 12 | RCT, Open-label | SYR-322-MET |
| NCT02337725 A Phase 3 Study of TVP-1012 (1 mg) in Early Parkinson's Disease Patients | Parkinson's Disease | P3 | Completed | 244 | RCT, Double-blind | TVP-1012, Placebo |
| NCT03245840 Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Participants With Eosinophilic Esophagitis (EoE) | Eosinophilic Esophagitis (EoE) | P3 | Terminated | 133 | Open-label | Budesonide oral suspension |
| NCT01467713 Efficacy and Safety of Ramelteon Sublingual as Adjunctive Therapy for Maintenance Treatment of Bipolar I Disorder | Bipolar Disorder | P3 | Terminated | 642 | RCT, Double-blind | Ramelteon SL, Placebo |
| NCT00091949 Insulin Resistance Intervention After Stroke Trial | Stroke, Myocardial Infarction | P3 | Completed | 3,876 | RCT, Double-blind | pioglitazone, placebo |
| NCT01738698 Adjunctive SPD489 to Antipsychotic Medication in Clinically Stable Adults With Persistent Predominant Negative Symptoms of Schizophrenia | Schizophrenia | P3 | Terminated | 4 | RCT, Double-blind | SPD489 40mg, SPD489 100mg, SPD489 160mg, Placebo |
| NCT00521820 Safety Comparison of Pioglitazone and Glyburide in Type 2 Diabetes Subjects With Mild to Moderate Congestive Heart Failure | Diabetes Mellitus | P3 | Terminated | 518 | RCT, Double-blind | Pioglitazone, Glyburide |
| NCT02093663 Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative Colitis | Ulcerative Colitis | P3 | Completed | 107 | RCT, Double-blind | MMX Mesalamine/Mesalazine (Low Dose), MMX Mesalamine/Mesalazine (High Dose) |
| NCT01632007 Double-blind Comparative Study of SYR-472 | Diabetes Mellitus | P3 | Completed | 245 | Double-blind | SYR-472, Alogliptin 25 mg, Placebo |
| NCT01452763 Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Low-dose Aspirin | Gastric Ulcers, Duodenal Ulcers | P3 | Completed | 621 | RCT, Double-blind | TAK-438, Placebo, TAK-438, Placebo, Lansoprazole, Placebo |
| NCT00150618 Safety and Efficacy of SPD503 in Treating ADHD in Children and Adolescents Aged 6-17 | Attention Deficit Disorder With Hyperactivity | P3 | Completed | 324 | RCT, Double-blind | SPD503 (1 mg), SPD503 (2 mg), SPD503 (3 mg), SPD503 (4 mg), Placebo |
| NCT01467700 Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder | Acute Depressive Episode | P3 | Terminated | 490 | RCT, Double-blind | Ramelteon SL, Placebo |
| NCT01485796 Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD | Primary Immunodeficiency Diseases (PID) | P2P3 | Completed | 54 | Open-label | Immune Globulin Infusion (Human), 10%, Recombinant human hyaluronidase |
| NCT00151918 Efficacy and Safety of Lanthanum Carbonate and Sevelamer Hydrochloride in Patients Receiving Haemodialysis for End Stage Renal Disease | Kidney Failure, Chronic | P3 | Completed | 48 | RCT, Open-label | Lanthanum carbonate |
| NCT02611830 Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative Colitis | Colitis, Ulcerative | P3 | Completed | 383 | RCT, Double-blind | Vedolizumab 300 mg IV, Placebo IV, Vedolizumab 108 mg SC, Placebo SC |
| NCT02388737 Efficacy and Safety of Vonoprazan Compared to Lansoprazole in the Maintenance Treatment of Erosive Esophagitis | Erosive Esophagitis | P3 | Completed | 703 | RCT, Double-blind | Vonoprazan, Lansoprazole, Vonoprazan Placebo, Lansoprazole Placebo |
| NCT00846365 Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension | Essential Hypertension | P3 | Completed | 1,085 | RCT, Double-blind | Azilsartan medoxomil and chlorthalidone, Azilsartan medoxomil and chlorthalidone, Olmesartan medoxomil-hydrochlorothiazide |
| NCT03888755 A Study of Icatibant for Acute Attacks of Hereditary Angioedema in Japanese Participants | Hereditary Angioedema (HAE) | P3 | Completed | 8 | Open-label | Icatibant |
| NCT01524887 Phase 3 IGIV, 10% in Alzheimer´s Disease | Alzheimer´s Disease | P3 | Terminated | 508 | RCT, Double-blind | Immune Globulin Intravenous (Human), 10% Solution, Human albumin 0.25% |
| NCT00255190 Safety and Quality of Life Study of Dexlansoprazole Modified Release Formulation to Treat Heartburn | Gastroesophageal Reflux Disease | P3 | Completed | 591 | RCT, Open-label | Dexlansoprazole MR, Dexlansoprazole MR |
| NCT00152022 Efficacy and Safety of SPD465 in Adults With Moderately Symptomatic ADHD. | Attention Deficit Disorder With Hyperactivity | P3 | Completed | 412 | RCT, Double-blind | Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulphate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate. |
| NCT00598442 Safety and Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis | Chronic Renal Failure, Chronic Kidney Disease | P3 | Completed | 493 | RCT, Open-label | peginesatide, peginesatide, Darbepoetin alfa |
| NCT02052141 Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema | Hereditary Angioedema (HAE) | P3 | Completed | 12 | RCT, Single-blind | CINRYZE 500, CINRYZE 1000 |
| NCT02845349 Vortioxetine for the Treatment of Major Depression and Co-morbidities After Traumatic Brain Injury (TBI) | TBI, Major Depression | P3 | Withdrawn | — | RCT, Double-blind | Vortioxetine, Placebo |
| NCT03393975 A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP) | Thrombotic Thrombocytopenic Purpura (TTP) | P3 | Completed | 52 | RCT, Open-label | TAK-755, Standard of care |
| NCT00255164 Efficacy and Safety of Dexlansoprazole MR on Maintaining Healing in Subjects With Healed Erosive Esophagitis | Esophagitis, Reflux, Esophagitis, Peptic | P3 | Completed | 451 | RCT, Double-blind | Dexlansoprazole MR, Dexlansoprazole MR, Placebo |
| NCT04779307 A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC) | Colitis, Ulcerative | P3 | Completed | 121 | RCT, Double-blind | Vedolizumab |
| NCT00630747 Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase | Hunter Syndrome, Mucopolysaccharidosis II (MPS II) | P2P3 | Completed | 94 | Open-label | Idursulfase |
| NCT02955355 Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | P3 | Completed | 85 | Open-label | HYQVIA |
| NCT00734578 Efficacy and Safety of SPD503 in Combination With Psychostimulants | ADHD | P3 | Completed | 461 | RCT, Double-blind | SPD503-AM, SPD503-PM, Placebo |
| NCT02337738 A Phase 2/3 Study of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Participants | Parkinson's Disease | P2P3 | Completed | 404 | RCT, Double-blind | TVP-1012 1mg, TVP-1012 0.5mg, Placebo |
| NCT00591578 Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Participants With Essential Hypertension | Hypertension | P3 | Completed | 984 | RCT, Double-blind | Azilsartan Medoxomil, Azilsartan Medoxomil, Valsartan |
| NCT03336450 Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Pediatric Patients With Status Epilepticus (Convulsive) in the Community Setting | Nervous System Diseases | P3 | Completed | 3 | Open-label | SHP615, MHOS/SHP615 |
| NCT01500135 Comparison of Efficacy and Safety of TachoSil® Versus Surgicel® Original for the Secondary Hemostatic Treatment of Needle Hole Bleeding in Vascular Surgery | Bleeding | P3 | Completed | 150 | RCT, Open-label | TachoSil®, Surgicel® Original |
| NCT00175019 Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010 | Gout | P3 | Completed | 1,086 | RCT, Open-label | Febuxostat, Febuxostat, Allopurinol |
| NCT00762112 Safety Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus | Diabetes Mellitus | P3 | Terminated | 316 | Open-label | TAK-559 |
| NCT01289119 Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes | Diabetes Mellitus, Type 2 | P3 | Completed | 506 | RCT, Double-blind | Alogliptin, Placebo to alogliptin, Metformin, Pioglitazone |
| NCT00798967 Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short Bowel Syndrome (SBS) Subjects | Short Bowel Syndrome | P3 | Completed | 86 | RCT, Double-blind | teduglutide, placebo |
| NCT00759720 Efficacy and Safety of TAK-559 Combined With Glyburide in Treating Subjects With Type 2 Diabetes Mellitus. | Diabetes Mellitus | P3 | Terminated | 447 | RCT, Double-blind | TAK-559 and glyburide, TAK-559 and glyburide, Glyburide |
| NCT00252694 DIabetic Retinopathy Candesartan Trials | Type 2 Diabetes | P3 | Completed | 4,717 | RCT, Double-blind | candesartan |
| NCT00457015 Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE) | Hereditary Angioedema (HAE) | P3 | Completed | 96 | RCT, Double-blind | ecallantide, Phosphate Buffer Saline (PBS), pH 7.0 |
| NCT01318083 Efficacy and Safety of Alogliptin Used in Combination With Sulfonylurea in Participants With Type 2 Diabetes in Japan | Type 2 Diabetes Mellitus | P2P3 | Completed | 312 | RCT, Double-blind | Alogliptin and glimepiride, Alogliptin and glimepiride, Glimepiride |
| NCT01488994 BAX 326 Pediatric Study | Hemophilia B | P2P3 | Completed | 23 | RCT, Open-label | BAX326 |
| NCT03748953 Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT) | Multiple Myeloma | P3 | Completed | 37 | Open-label | Ixazomib |
| NCT01193244 Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer | Prostate Cancer | P3 | Completed | 1,560 | RCT, Double-blind | Orteronel, Placebo, Prednisone |
| NCT00438815 Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks | Hereditary Angioedema | P3 | Completed | 113 | Open-label | C1 esterase inhibitor [human] (C1INH-nf) |
| NCT02139046 Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout | Gout | P3 | Completed | 1,790 | RCT, Double-blind | Febuxostat IR, Febuxostat XR, Febuxostat placebo, Colchicine, Naproxen, Lansoprazole |
| NCT02210091 BAX 855 Pediatric Study | Hemophilia A | P3 | Completed | 75 | Open-label | Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method, PEGylated Recombinant Factor VIII, PEGylated Recombinant Factor VIII |
| NCT00762359 A Safety and Efficacy Study of Lansoprazole in Preventing Aspirin-Induced Gastric and Duodenal Ulcers | Stomach Ulcer, Duodenal Ulcer | P3 | Terminated | 461 | RCT, Double-blind | Lansoprazole, Gefarnate |
| NCT00851721 Efficacy and Safety Study of Prophylactic Versus On-Demand Treatment With Feiba NF in Subjects With Hemophilia A or B and a High Titer Inhibitor | Hemophilia A or B With Inhibitors, Hemophilia A | P3 | Completed | 52 | RCT, Open-label | Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated), Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) |
| NCT01718483 SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder | Binge Eating Disorder | P3 | Completed | 383 | RCT, Double-blind | SPD489 (Lisdexamfetamine dimesylate), Placebo |
| NCT01718509 SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder | Binge Eating Disorder | P3 | Completed | 390 | RCT, Double-blind | SPD489 (Lisdexamfetamine dimesylate), Placebo |
| NCT00150540 A Long Term Study of Lanthanum Carbonate in Patients Requiring Dialysis Who Have Ived Lanthanum Carbonate in Previous Studies Defined by the Protocol. | Kidney Failure, Chronic | P3 | Completed | 93 | Open-label | Lanthanum carbonate |
| NCT00441545 Head to Head Study Against Sevelamer Hydrochloride | Chronic Kidney Disease, Stage 5 | P3 | Completed | 182 | RCT, Open-label | Fosrenol (Lanthanum Carbonate), Sevelamer hydrochloride |
| NCT00731120 Study of Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder | Generalized Anxiety Disorder | P3 | Completed | 457 | RCT, Double-blind | Vortioxetine, Placebo |
| NCT00722137 Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma | Mantle Cell Lymphoma | P3 | Completed | 487 | RCT, Open-label | Rituximab 375 mg/m^2, Cyclophosphamide 750 mg/m^2, Doxorubicin 50 mg/m^2, VELCADE 1.3 mg/m^2, Prednisone 100 mg/m^2, Vincristine 1.4 mg/m^2 |
| NCT00261300 Long-term Pantoprazole Trial in Patients With Symptoms of Chronic Acid Peptic Complaints (BY1023/VMG-708) | Gastroesophageal Reflux Disease (GERD), Peptic Ulcers | P3 | Completed | 100 | Open-label | Pantoprazole |
| NCT02337751 A Phase 3, Long-term, Extension Study of TVP-1012 (1 mg) in Early Parkinson's Disease Participants | Parkinson's Disease | P3 | Completed | 198 | Open-label | TVP-1012 1mg |
| NCT01011751 Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Prostate Adenocarcinoma | Adenocarcinoma, Prostate | P3 | Completed | 311 | RCT, Double-blind | Cyproterone acetate, Medroxyprogesterone acetate, Venlafaxine, Leuprorelin, Flutamide, Placebo |
| NCT00737347 Prevention of Weight Gain in Adult Patients With Type 2 Diabetes Treated With Pioglitazone | Type 2 Diabetes, Obesity | P3 | Completed | 39 | RCT, Open-label | — |
| NCT05529992 A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adults With Type 1 Gaucher Disease | Gaucher Disease | P3 | Completed | 20 | Open-label | Velaglucerase Alfa |
| NCT01455181 A Study to Investigate the Safety and Tolerability of NPSP558, for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study in Hungary | Hypoparathyroidism | P3 | Completed | 24 | Open-label | NPSP558 |
| NCT02931539 Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir | Cytomegalovirus (CMV) | P3 | Completed | 352 | RCT, Open-label | Maribavir, Ganciclovir, Valganciclovir, Foscarnet, Cidofovir |
| NCT00633477 Efficacy and Safety of Resatorvid in Patients With Sepsis-induced Cardiovascular and Respiratory Failure | Sepsis | P3 | Terminated | 18 | RCT, Double-blind | Resatorvid, Placebo |
| NCT03268811 A Study in Japanese Children With Short Bowel Syndrome Who Completed SHP633-302 | Short Bowel Syndrome | P3 | Completed | 9 | Open-label | Teduglutide |
| NCT06422377 A Study Evaluating Soticlestat in Participants With Dravet Syndrome or Lennox-Gastaut Syndrome Who Have Been Exposed to Fenfluramine | Dravet Syndrome (DS), Lennox-Gastaut Syndrome (LGS) | P3 | Terminated | 1 | Open-label | Soticlestat |
| NCT05513586 A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) Participants | Primary Immunodeficiency Diseases (PID) | P3 | Completed | 15 | Open-label | TAK-771 |
| NCT00591773 Efficacy and Safety of Azilsartan Medoxomil Co-Administered With Chlorthalidone in Participants With Essential Hypertension | Hypertension | P3 | Completed | 551 | RCT, Double-blind | Azilsartan medoxomil and chlorthalidone, Azilsartan medoxomil and chlorthalidone, Chlorthalidone |
| NCT01274221 Safety and Efficacy of SPD489 in Adolescent Subjects Aged 13-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD) | ADHD | P3 | Withdrawn | — | RCT, Double-blind | SPD489 |
| NCT00775840 Efficacy of Candesartan on Symptomatic Heart Failure in Treating Diabetic and Hypertensive Patients. | Heart Failure | P3 | Completed | 22 | RCT, Double-blind | Candesartan, Placebo |
| NCT01005888 C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks | Hereditary Angioedema | P3 | Completed | 26 | RCT, Double-blind | C1 esterase inhibitor [human] (C1INH-nf), Placebo (saline) |
| NCT01760889 SPD489 Low Dose and High Dose Ranges When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia | Schizophrenia | P3 | Terminated | 1 | RCT, Double-blind | SPD489 low dose range (40mg, 80mg, and 100mg), SPD489 high dose range (120mg, 140mg and 160mg), Placebo |
| NCT01751360 SYR-472 Open-label Study | Diabetes Mellitus | P3 | Completed | 14 | — | SYR-472 |
| NCT00497796 Maribavir Versus Oral Ganciclovir For The Prevention of Cytomegalovirus (CMV) Disease in Liver Transplant Recipients | Cytomegalovirus Infections | P3 | Completed | 307 | RCT, Double-blind | maribavir, ganciclovir |
| NCT01456169 A Study to Evaluate the Effectiveness and Safety of a Fixed Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With High Blood Pressure Who do Not Achieve Target Blood Pressure Following Treatment With Azilsartan Medoxomil Alone | Essential Hypertension | P3 | Completed | 507 | RCT, Double-blind | Azilsartan medoxomil/placebo, Azilsartan medoxomil - chlorthalidone |
| NCT01355627 TASALL - TachoSil® Against Liquor Leak | Cerebrospinal Fluid Leaks | P3 | Completed | 726 | RCT, Open-label | — |
| NCT02727777 Phase II Study of TAK228 in Relapsed Lymphoma | Lymphoma | P1P2 | Terminated | 4 | Open-label | TAK228 |
| NCT01549977 Effect of Febuxostat Compared to Placebo on Exercise Tolerance in Participants With Chronic Stable Angina | Angina | P2 | Terminated | 1 | RCT, Double-blind | Febuxostat, Placebo |
| NCT00254267 Evaluate the Efficacy of AMG 706 to Treat Advanced Gastrointestinal Stromal Tumors | Advanced Gastrointestinal Stromal Tumor | P2 | Completed | 35 | Open-label | AMG 706 |
| NCT01298492 A Study To Monitor Long-Term Treatment With PF-00547659 | Crohn's Disease | P2 | Completed | 268 | — | PF-00547659 |
| NCT02916771 Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma | Smoldering Multiple Myeloma | P2 | Completed | 61 | Open-label | Ixazomib, Lenalidomide, Dexamethasone |
| NCT03694275 A Multicenter, Open-label, Pilot Study of Soticlestat (TAK-935/OV935) in Participants With 15Q Duplication Syndrome (Dup 15q) or Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder (ARCADE STUDY) | 15q Duplication Syndrome, CDKL5 Deficiency Disease | P2 | Completed | 20 | Open-label | Soticlestat |
| NCT01299727 Extension of Study HGT-SAN-055 Evaluating Administration of rhHNS in Patients With Sanfilippo Syndrome Type A (MPS IIIA) | Sanfilippo Syndrome | P1P2 | Terminated | 12 | Open-label | rhHNS-10 mg, rhHNS-45 mg, rhHNS-90 mg |
| NCT02993094 Ixazomib (MLN9708) in Combination With Carboplatin in Pretreated Women With Advanced Triple Negative Breast Cancer | Triple-Negative Breast Cancer | P1P2 | Terminated | 31 | Open-label | Ixazomib, Carboplatin |
| NCT00312286 Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women. | Papillomavirus Infections | P2 | Terminated | 538 | RCT, Double-blind | 851B, 851B, 851B, 851B, 851B, 851B, 851B, 851B, 851B, 851B, 851B |
| NCT00012259 Troxacitabine in Treating Patients With Chronic Myelogenous Leukemia | Leukemia | P2 | Completed | 31 | Open-label | troxacitabine |
| NCT01806584 An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Placement of an Arteriovenous Graft to Facilitate Hemodialysis Access | Arteriovenous Graft | P2 | Terminated | 32 | RCT, Single-blind | SRM003 |
| NCT01084655 Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer | Prostate Cancer | P1P2 | Completed | 38 | Open-label | TAK-700, Docetaxel, Prednisone |
| NCT00308438 Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease Who Completed Protocol CL0600-008 | Crohn's Disease | P2 | Completed | 67 | Open-label | Teduglutide (ALX-0600) |
| NCT03732703 Myeloma-Developing Regimens Using Genomics (MyDRUG) | Relapsed Refractory Multiple Myeloma | P1P2 | Completed | 103 | Open-label | Abemaciclib, dexamethasone, ixazomib, pomalidomide, Enasidenib, dexamethasone, ixazomib, pomalidomide, Cobimetinib, dexamethasone, ixazomib, pomalidomide, Erdafitinib, dexamethasone, ixazomib, pomalidomide, Venetoclax, dexamethasone, ixazomib, pomalidomide, Daratumumab, dexamethasone, ixazomib, pomalidomide, Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide, Selinexor, dexamethasone, ixazomib, pomalidomide |
| NCT02919501 Study of the Efficacy and Safety of Initial Administration of 17 mg Vortioxetine Intravenously With 10 mg/Day Vortioxetine Orally in Patients With Major Depressive Disorder | Depressive Disorder, Major | P2 | Completed | 55 | RCT, Double-blind | Vortioxetine (IV), Vortioxetine (tablet) |
| NCT02083185 A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer | Prostate Cancer | P2 | Completed | 136 | RCT, Open-label | Relugolix, Leuprorelin |
| NCT02006056 Ondissolve in the Prophylaxis/Rescue of Radiation Induced Nausea and Vomiting | Nausea, Vomiting | P2 | Completed | 30 | Open-label | Ondansetron |
| NCT04159805 A Study of TAK-079 in People With Generalized Myasthenia Gravis | Myasthenia Gravis | P2 | Completed | 36 | RCT, Double-blind | TAK-079, TAK-079 Placebo |
| NCT02948829 Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children | Healthy Volunteers | P2 | Completed | 200 | Open-label | TDV |
| NCT04381650 A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors | Advanced or Metastatic Solid Tumors | P1P2 | Completed | 161 | Open-label | TAK-981, Pembrolizumab |
| NCT02929316 Vedolizumab Induction May Prevent Celiac Enteritis | Celiac Disease | P2 | Terminated | 1 | Open-label | Vedolizumab |
| NCT04278924 A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia | Primary Immune Thrombocytopenia | P2 | Completed | 41 | RCT, Double-blind | Placebo, TAK-079 |
| NCT00545389 Phase II Dose-Ranging Study in Subjects With Mild to Moderate Ulcerative Colitis Treated With SPD476 | Colitis, Ulcerative | P2 | Completed | 38 | RCT, Double-blind | SPD476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine |
| NCT03535740 A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib | ALK-positive Advanced NSCLC | P2 | Completed | 103 | Open-label | Brigatinib |
| NCT07319845 A Study of TAK-226 for Transfusion-Dependent Anemia in Japanese Patients With Lower-Risk Myelodysplastic Syndromes | Myelodysplastic Syndromes | P2 | Not Yet Recruiting | 27 | Open-label | TAK-226 |
| NCT00174941 Long-Term Safety of Febuxostat in Subjects With Gout. | Gout | P2 | Completed | 116 | Open-label | Febuxostat, Febuxostat, Febuxostat |
| NCT02204579 A Study to Determine the Effects of NPSP795 on the Calcium-sensing Receptor in Subjects With Autosomal Dominant Hypocalcemia as Measured by PTH Levels and Blood Calcium Concentrations | Autosomal Dominant Hypocalcemia (ADH) | P2 | Completed | 7 | Open-label | NPSP795 |
| NCT02477020 A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia | Schizophrenia | P2 | Completed | 164 | RCT, Double-blind | TAK-063 20 mg, Placebo |
| NCT02441309 A Eurosarc Study of Mifamurtide in Advanced Osteosarcoma (MEMOS) | Osteosarcoma | P2 | Terminated | 8 | RCT, Open-label | Mifamurtide, Ifosfamide |
| NCT01771809 Long-Term Safety Of PF-00547659 In Ulcerative Colitis | Ulcerative Colitis | P2 | Completed | 330 | RCT, Open-label | 75mg SHP647 (PF-00547659), 225mg SHP647 (PF-00547659) |
| NCT01363908 Safety, Efficacy and Pharmacokinetics of an Oral Iron Chelator Given for a Year to Pediatric Patients With Iron Overload | Transfusional Iron Overload, Beta-Thalassemia | P2 | Terminated | 30 | Open-label | SPD602 |
| NCT01874665 A Phase 2 Trial of Ponatinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor | GIST | P2 | Completed | 45 | Open-label | Ponatinib |
| NCT01091428 Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer | Ovarian Carcinoma, Fallopian Tube Cancer | P2 | Completed | 191 | RCT, Double-blind | Alisertib, Paclitaxel |
| NCT02540356 Phase 1/2a Two-Arm Dose-Escalation Study of BAX69 in Subjects With Malignant Ascites of Ovarian Cancer | Refractory Ovarian Cancer With Recurrent Symptomatic Malignant Ascites | P1P2 | Terminated | 2 | Open-label | BAX69 Single-Route Arm, BAX69 Double-Route Arm |
| NCT07613359 A Study of Mezagitamab in Adults With Late Antibody-Mediated Rejection (AMR) After a Kidney Transplant | Antibody-Mediated Rejection (AMR) | P2 | Not Yet Recruiting | 36 | RCT, Double-blind | Mezagitamab, Placebo |
| NCT00752791 Efficacy and Safety of Peginesatide Injection for the Maintenance Treatment of Anemia in Peritoneal Dialysis Participants Previously Treated With Epoetin. | Anemia | P2 | Completed | 59 | Open-label | Peginesatide |
| NCT00413634 The Pharmacokinetics of Anagrelide in Elderly and Young Patients With Essential Thrombocythaemia (ET) | Essential Thrombocythaemia | P2 | Completed | 24 | Open-label | anagrelide hydrochloride, anagrelide hydrochloride |
| NCT02410499 Efficacy and Safety of Weekly Subcutaneous MLN1202 in Improving Diabetic Nephropathy in Participants With Macroalbuminuria | Diabetic Nephropathy | P2 | Withdrawn | — | RCT, Double-blind | MLN1202 Placebo, MLN1202 |
| NCT03439293 A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM) | Multiple Myeloma | P2 | Completed | 61 | Open-label | Ixazomib, Daratumumab, Dexamethasone |
| NCT02350816 An Extension Study to Determine Safety and Efficacy for Pediatric Patients With MPS Type IIIA Disease Who Participated in Study HGT-SAN-093. | Sanfilippo Syndrome, Mucopolysaccharidosis (MPS) | P2 | Terminated | 17 | RCT, Open-label | HGT-1410 |
| NCT01667133 A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL) | Chronic Myeloid Leukemia (CML), Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) | P1P2 | Completed | 35 | Open-label | ponatinib - Phase 1, ponatinib - Phase 2 |
| NCT03746652 Safety and Efficacy of Daratumumab in Combination With Ixazomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | Multiple Myeloma | P2 | Unknown | 50 | Open-label | Daratumumab, Ixazomib, Dexamethasone |
| NCT04079738 Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib | AML, AML, Adult | P1P2 | Terminated | 8 | Open-label | TAK-659, Ixazomib |
| NCT01620255 A Study Of PF-00547659 In Patients With Moderate To Severe Ulcerative Colitis | Ulcerative Colitis | P2 | Completed | 357 | RCT, Double-blind | Placebo, PF-00547659 SC Injection, PF-00547659 SC Injection, PF-00547659 SC Injection, PF-00547659 SC Injection |
| NCT04576208 A Study to Evaluate the Impact of Management Strategies on Gastrointestinal-Related Adverse Events in Participants With Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations Receiving TAK-788 | Non-Small Cell Lung Cancer (NSCLC) | P2 | Withdrawn | — | RCT, Open-label | TAK-788, Antidiarrheal prophylaxis |
| NCT00770497 Efficacy Study of Pioglitazone and Ramipril Combination Therapy in Treating Non-diabetic Hypertensive Patients. | Inflammation, Hypertension | P2 | Completed | 172 | RCT, Double-blind | Pioglitazone, Pioglitazone and ramipril, Ramipril |
| NCT05220098 First-in-Human Study of TAK-280 in Participants With Solid Tumors | Unresectable Locally Advanced or Metastatic Cancer | P1P2 | Terminated | 69 | RCT, Open-label | TAK-280 |
| NCT01289132 Efficacy and Safety of Azilsartan in Participants With Mild to Moderate Uncomplicated Essential Hypertension | Essential Hypertension | P2 | Completed | 926 | RCT, Double-blind | Placebo, Azilsartan, Azilsartan, Azilsartan, Azilsartan, Azilsartan, Candesartan cilexetil |
| NCT00739024 A Study of a Melatonin Receptor Agonist to Prevent Migraine | Migraine, Migraine With Aura | P2 | Terminated | 18 | RCT, Double-blind | Ramelteon, Placebo |
| NCT02332824 A Phase 2 Dose-finding Study of TAK-272 in Participants With Type 2 Diabetes Mellitus and Microalbuminuria | Type 2 Diabetes Mellitus and Microalbuminuria | P2 | Completed | 415 | RCT, Double-blind | TAK-272, TAK-272 Placebo, Candesartan cilexetil, Candesartan cilexetil Placebo |
| NCT02713061 A Phase 2 Study of a Subcutaneous Injection of TAK-850 in Healthy Adult Participants | Influenza Prevention | P2 | Withdrawn | — | Open-label | TAK-850 |
| NCT02388971 Proof of Mechanism Study of MLN1202 on Atherosclerotic Inflammation in Participants With Stable Atherosclerotic Cardiovascular Disease | Atherosclerotic Cardiovascular Disease | P2 | Withdrawn | — | RCT, Double-blind | MLN1202, Placebo |
| NCT00763347 Efficacy and Safety Study of SYR-619 in Treating Subjects With Type 2 Diabetes Mellitus | Diabetes Mellitus | P2 | Terminated | 82 | RCT, Double-blind | SYR-619, SYR-619, SYR-619, SYR-619, Placebo, Alogliptin |
| NCT02101684 Orteronel (TAK-700) in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors. The Greko II Study. | Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors | P2 | Terminated | 10 | Open-label | Orteronel 300mg BID |
| NCT02046070 Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma | Multiple Myeloma | P2 | Completed | 148 | RCT, Open-label | Cyclophosphamide, Ixazomib, Dexamethasone |
| NCT03608501 A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation | Multiple Myeloma | P2 | Withdrawn | — | Open-label | Ixazomib, Thalidomide, Dexamethasone |
| NCT02897830 Ixazomib, Lenalidomide, Dexamethasone Induction and Extended Consolidation Plus Lenalidomide Maintenance in Multiple Myeloma | Multiple Myeloma | P2 | Terminated | 46 | Open-label | Ixazomib, Lenalidomide, Dexamethasone |
| NCT01147302 A Pilot Study to Evaluate the Use of C1 Esterase Inhibitor (Human) in Patients With Acute Antibody-Mediated Rejection | Graft Rejection | P2 | Completed | 18 | RCT, Double-blind | Placebo, C1 Esterase Inhibitor (Human) |
| NCT00982202 Pioglitazone in Alzheimer Disease | Alzheimer Disease | P2 | Completed | 25 | RCT, Double-blind | pioglitazone, Placebo |
| NCT02367885 Phase 1/2 Study of TAK-850 Intramuscular Injection in Healthy Pediatric Participants | Influenza Infection | P1P2 | Completed | 99 | Open-label | TAK-850 0.5 mL injection, TAK-850 0.25 mL injection |
| NCT03138655 Vedolizumab IV in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD) | Ulcerative Colitis, Crohn's Disease | P2 | Completed | 89 | RCT, Double-blind | Vedolizumab |
| NCT00755508 Efficacy and Safety of Ramelteon Combined With Gabapentin in Treating Patients With Insomnia | Sleep Initiation and Maintenance Disorders | P2 | Completed | 378 | RCT, Double-blind | Ramelteon and gabapentin, Ramelteon and gabapentin, Ramelteon, Gabapentin, Placebo |
| NCT00987142 Trial To Assess Efficacy Of A Chimeric Skin In Patients With Epidermolysys Bullosa | EPIDERMOLYSIS BULLOSA | P2 | Completed | 12 | Open-label | CX501 |
| NCT03738475 Study of the Safety, Pharmacodynamics, Efficacy, and PK of TIMP-GLIA in Subjects With Celiac Disease | Celiac Disease | P2 | Completed | 34 | RCT, Double-blind | TIMP-GLIA, Placebo |
| NCT05526391 A Study of TAK-341 in Treatment of Multiple System Atrophy | Multiple System Atrophy | P2 | Completed | 158 | RCT, Double-blind | Placebo, TAK-341 |
| NCT03370172 A Study of BAX 888 in Male Adults With Severe Hemophilia A | Hemophilia A | P1P2 | Completed | 4 | Open-label | BAX 888 |
| NCT00882687 Efficacy Study to Evaluate the Effectiveness of 3 Concentrations of SAR 1118 in Allergic Conjunctivitis | Allergic Conjunctivitis | P2 | Completed | 60 | RCT, Double-blind | Lifitegrast |
| NCT02393378 Namilumab vs Adalimumab in Participants With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to Methotrexate | Rheumatoid Arthritis | P2 | Terminated | 7 | RCT, Open-label | Namilumab, Adalimumab, Methotrexate, Folic Acid |
| NCT00915135 Efficacy and Safety of Ramelteon on Chronic Insomnia | Chronic Insomnia | P2 | Completed | 66 | RCT, Double-blind | Ramelteon and Placebo (25 possible combinations total) |
| NCT02153112 Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle (VLP) Vaccine in Children | Norovirus | P2 | Completed | 840 | RCT, Double-blind | GI.1/GII.4 (15/15), GI.1/GII.4 (15/50), GI.1/GII.4 (50/50), GI.1/GII.4 (50/150), Placebo |
| NCT01276509 Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease | Crohn's Disease | P2 | Completed | 265 | RCT, Double-blind | PF-00547659 SC injection, PF-00547659 SC injection, PF-00547659 SC injection, PF-00547659 SC injection |
| NCT03547700 Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL) | Lymphoma, T-Cell, Peripheral | P1P2 | Terminated | 11 | Open-label | Romidepsin, Ixazomib |
| NCT03158727 Cx611-0204 SEPCELL Study | Bacterial Pneumonia | P1P2 | Completed | 84 | RCT, Double-blind | Cx611 |
| NCT01263470 Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes in Japan | Diabetes Mellitus, Type 2 | P2 | Completed | 480 | RCT, Double-blind | Alogliptin, Alogliptin, Alogliptin, Alogliptin, Voglibose, Placebo |
| NCT01953081 A Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of a Single Dose of Intravenous TD-8954 Compared With Metoclopramide in Critically Ill Patients With Enteral Feeding Intolerance | Enteral Feeding Intolerance | P1P2 | Completed | 13 | RCT, Double-blind | TD-8954, Metoclopramide |
| NCT05153148 A Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Participants With Active Psoriatic Arthritis | Psoriatic Arthritis | P2 | Completed | 305 | RCT, Double-blind | NDI-034858 |
| NCT01848067 Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer | Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer | P1P2 | Completed | 9 | Open-label | Alisertib, Abiraterone acetate, Prednisone |
| NCT07648030 A Study of Rusfertide in Japanese Adults With Polycythemia Vera | Polycythemia Vera | P2 | Not Yet Recruiting | 9 | Open-label | Rusfertide |
| NCT00922272 Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms | Schizophrenia and Predominant Negative Symptoms | P2 | Completed | 92 | RCT, Double-blind | SPD489 (lisdexamfetamine dimesylate), Placebo matching SPD489 (lisdexamfetamine dimesylate) |
| NCT01510028 Multicenter Study of HGT-1110 Administered Intrathecally in Children With Metachromatic Leukodystrophy (MLD) | Metachromatic Leukodystrophy (MLD) | P1P2 | Completed | 24 | Open-label | Recombinant human arylsulfatase A |
| NCT00807495 Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma | Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma | P2 | Completed | 48 | Open-label | Alisertib |
| NCT02337946 Safety and Efficacy Study of mFOLFOX6 + Panitumumab Combination Therapy and 5-FU/LV + Panitumumab Combination Therapy in Participants With Chemotherapy-naïve Unresectable Advanced Recurrent Colorectal Carcinoma | Colorectal Carcinoma | P2 | Completed | 164 | RCT, Open-label | oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab, oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab |
| NCT01435759 SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder | Major Depressive Disorder | P2 | Completed | 1,197 | RCT, Double-blind | Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg, Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 30 mg, Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 50 mg, Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 70 mg, Antidepressant + Placebo |
| NCT02467270 Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses | Myeloid Leukemia, Chronic, Chronic Phase | P2 | Completed | 283 | RCT, Open-label | Ponatinib |
| NCT01099215 Study of PVS-10200 for the Treatment of Restenosis in Patients With Peripheral Artery Disease (TRIUMPH) | Peripheral Artery Disease | P1P2 | Completed | 21 | Open-label | PVS-10200 |
| NCT01207440 Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL) | Chronic Myeloid Leukemia, Ph+ Acute Lymphoblastic Leukemia | P2 | Completed | 449 | Open-label | Ponatinib |
| NCT02369796 A Phase 2a Pharmacodynamic Study of TAK-448 in Participants With Hypogonadotropic Hypogonadism | Hypogonadotropic Hypogonadism | P2 | Terminated | 15 | Open-label | TAK-448 |
| NCT01291173 Forced-dose Titration of SPD489 in Adults With Binge Eating Disorder | Binge Eating Disorder | P2 | Completed | 271 | RCT, Double-blind | lisdexamfetamine dimesylate (SPD489), lisdexamfetamine dimesylate (SPD489), lisdexamfetamine dimesylate (SPD489), Placebo |
| NCT03943446 A Study of TAK-018 in Preventing the Recurrence of Crohn's Disease After Surgery | Crohn Disease | P2 | Terminated | 34 | RCT, Double-blind | TAK-018, TAK-018 Placebo |
| NCT03131895 Bioequivalence Study of Dexlansoprazole Capsules From Two Manufacturing Plants | Healthy Volunteers | P1 | Completed | 116 | RCT, Open-label | 30 mg dexlansoprazole capsules manufactured at TOB, 30 mg dexlansoprazole capsules manufactured at TPC, 60 mg dexlansoprazole capsules manufactured at TOB, 60 mg dexlansoprazole capsules manufactured at TPC |
| NCT02045095 A Dose Escalation Study of MLN7243 (TAK-243) in Adult Participants With Advanced Solid Tumors | Advanced Malignant Solid Tumors | P1 | Terminated | 29 | Open-label | MLN7243 |
| NCT06268301 A Study to Determine the Effect Food Has on TAK-721 (Budesonide Oral Suspension) in the Body of Healthy Adults | Healthy Volunteers | P1 | Completed | 20 | RCT, Open-label | Budesonide |
| NCT03522506 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of TAK-925 Study in Sleep-Deprived Healthy Adults | Healthy Volunteers | P1 | Completed | 20 | RCT, Double-blind | TAK-925, TAK-925 Placebo, Modafinil, Modafinil Placebo |
| NCT01765426 Phase 1b Study Investigating Safety & Immunogenicity of TDV Given Intradermally by Needle or Needle-Free PharmaJet Injector | Healthy Volunteers | P1 | Completed | 67 | RCT, Double-blind | TDV, Placebo |
| NCT01898078 Food Effect Study of Alisertib (MLN8237) in Participants With Advanced Solid Tumors or Lymphomas | Advanced Solid Tumors, Lymphoma | P1 | Completed | 26 | RCT, Open-label | Alisertib |
| NCT04091438 A Study of a Single Intravenous Infusion Dose of TAK-925 in Participants With Idiopathic Hypersomnia | Idiopathic Hypersomnia | P1 | Completed | 28 | RCT, Double-blind | TAK-925, TAK-925 Placebo |
| NCT03808493 A Bioequivalence (BE) Study of TAK-438 Orally Disintegrating (OD) Tablet | Japanese Healthy Adult Male | P1 | Completed | 48 | RCT, Open-label | TAK-438 OD, TAK-438 |
| NCT04454918 Study to Assess Absolute Bioavailability (ABA) of TAK-906 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]-TAK-906 in Healthy Male Participants | Healthy Volunteers | P1 | Completed | 6 | Open-label | TAK-906 Oral Capsule, [14C]-TAK-906 Intravenous Infusion, [14C]-TAK-906 Oral Solution |
| NCT01045096 Study to Evaluate the Pharmacokinetics and Safety of Dexlansoprazole in Pediatric Subjects With Symptomatic Gastroesophageal Reflux Disease | Gastroesophageal Reflux | P1 | Completed | 36 | RCT, Open-label | Dexlansoprazole, Dexlansoprazole, Dexlansoprazole |
| NCT03928327 A Study to Evaluate Drug-Drug Interaction of TAK-788 With Itraconazole and Rifampin in Healthy Adult Participants | Healthy Volunteers | P1 | Completed | 24 | Open-label | TAK-788, Itraconazole, Rifampin |
| NCT05976321 A Study of TAK-279 in Adults With or Without Liver Damage | Hepatic Impairment, Healthy Volunteers | P1 | Completed | 27 | Open-label | TAK-279 |
| NCT01728792 Impact of SC vs IM Administration of DENVax (TDV) on Safety and Immunogenicity | Dengue Fever | P1 | Completed | 80 | RCT, Open-label | TDV |
| NCT01299805 Effects of Vortioxetine (Lu AA21004) on the Concentrations of Selected Neurotransmitters in Healthy Male Adults | Healthy | P1 | Completed | 17 | RCT, Single-blind | Vortioxetine, Placebo |
| NCT02774902 TAK-438_110 Drug Interaction With Cytochrome P450 3A4 (CYP3A4) Inhibitor Clarithromycin | Healthy Volunteers | P1 | Completed | 16 | Open-label | TAK-438, Clarithromycin |
| NCT02113020 A Phase I Clinical Pharmacology Study of TAK-233 in Healthy Subjects | Clinical Pharmacology | P1 | Completed | 24 | RCT, Double-blind | TAK-233, Placebo |
| NCT03748979 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-925 in Healthy Volunteers and Participants With Narcolepsy | Healthy Participants, Narcolepsy | P1 | Completed | 57 | RCT, Double-blind | TAK-925, Placebo |
| NCT07052682 A Study to Evaluate How Ontamalimab Works and Assess Its Safety and Tolerability in People With Nonalcoholic Steatohepatitis With Fibrosis Stages 1 to 4 | Steatohepatitis | P1 | Terminated | 11 | Open-label | Ontamalimab |
| NCT02584569 Phase 1 TAK-915 Single-Dose Positron Emission Tomography (PET) Occupancy Study | Healthy Volunteers | P1 | Completed | 12 | Open-label | TAK-915 |
| NCT01905553 The Effect of Food on the Bioavailability of a Single Dose of SSP-004184SS in Healthy Adult Subjects | Healthy | P1 | Completed | 9 | RCT, Open-label | SSP-004184SS |
| NCT04731922 A Study of TAK-510 in Healthy Adults | Healthy Participants | P1 | Completed | 124 | RCT, Double-blind | TAK-510, TAK-510 Placebo |
| NCT01541670 Safety Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Lupus Nephritis | Systemic Lupus Erythematosus | P1 | Terminated | 4 | Open-label | Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody |
| NCT00914862 Pharmacokinetic and Safety of Ramelteon Between Adolescents With Insomnia and Healthy Adults | Insomnia | P1 | Completed | 56 | RCT, Open-label | Ramelteon |
| NCT04091425 Study of TAK-925 in Participants With Obstructive Sleep Apnea (OSA) Who Are Experiencing Excessive Daytime Sleepiness (EDS) Despite Adequate Use of Continuous Positive Airway Pressure (CPAP) | Obstructive Sleep Apnea | P1 | Completed | 25 | RCT, Double-blind | TAK-925, Placebo |
| NCT04441255 A Study to Evaluate the Effect of High-Fat Meal on TAK-788 Pharmacokinetics (PK) in Healthy Adult Participants | Healthy Volunteers | P1 | Completed | 14 | RCT, Open-label | TAK-788 |
| NCT05976334 An Absorption, Distribution, Metabolism, Excretion (ADME) Study of [14C]Subasumstat in Adults With Advanced or Metastatic Solid Tumors | Solid Tumors | P1 | Terminated | 3 | Open-label | [14C] Subasumstat, Subasumstat |
| NCT00816660 Pharmacokinetic, Safety and Tolerability Study of Recombinant Von Willebrand Factor / Recombinant Factor VIII Complex in Type 3 Von Willebrand Disease | Von Willebrand Disease | P1 | Completed | 32 | RCT, Single-blind | Recombinant von Willebrand factor : recombinant FVIII (rVWF:rFVIII), Marketed plasma-derived VWF/FVIII concentrate |
| NCT01376479 Safety and Immunogenicity Study of an Inactivated Vaccine Against Hand, Foot and Mouth Disease Caused by Enterovirus 71 | Hand, Foot and Mouth Disease | P1 | Completed | 36 | RCT, Double-blind | INV21 Low Dose, INV21 High Dose, Placebo |
| NCT01317797 A Trial to Evaluate the Safety and Tolerability of Namilumab (MT203) in Patients With Mild to Moderate Rheumatoid Arthritis | Rheumatoid Arthritis | P1 | Completed | 24 | RCT, Double-blind | namilumab (MT203), Placebo |
| NCT03327402 Safety, Tolerability and Pharmacokinetics of SHP465 in Children Aged 4 to 5 Years With Attention-Deficit/Hyperactivity Disorder (ADHD) | Attention Deficit Hyperactivity Disorder (ADHD) | P1 | Completed | 24 | Open-label | SHP465 |
| NCT02367872 Phase I Open-label Study to Evaluate Pharmacokinetics of TAK-272 in Participants With Renal or Hepatic Impairment | Renal Impairment, Hepatic Impairment | P1 | Completed | 48 | Open-label | TAK-272 |
| NCT06610279 A Study of TAK-951 in Healthy Adults | Healthy Volunteers | P1 | Terminated | 48 | RCT, Double-blind | TAK-951, Placebo |
| NCT00220818 A Study to Evaluate the Effect of Lansoprazole on Infants With Gastroesophageal Reflux Disease. | Gastroesophageal Reflux Disease | P1 | Completed | 24 | RCT, Open-label | Lansoprazole, Lansoprazole |
| NCT01899053 A Safety and Pharmacokinetic Study of TAK-228 in Combination With TAK-117 in Adult Participants With Advanced Nonhematologic Malignancies | Advanced Nonhematologic Malignancies | P1 | Completed | 101 | Open-label | TAK-228, TAK-117 |
| NCT01311076 TAK-329 Glucose Clamp Study | Type 1 Diabetes Mellitus | P1 | Completed | 37 | RCT, Double-blind | TAK-329, TAK-329, Insulin, Placebo |
| NCT02338713 Effect of Calcium 500 mg and Vitamin D3 1000 IU Chewable Tablet on Intestinal Calcium Absorption | Healthy Volunteers | P1 | Completed | 27 | Open-label | Calcichew D3, Noncarbonated Water |
| NCT03237156 Phase 1 TAK-906 Single and Multiple Ascending Dose Study in Japanese Healthy Male Participants | Japanese Healthy Adult Male Participants | P1 | Completed | 24 | RCT, Double-blind | TAK-906, TAK-906 Placebo |
| NCT03085836 A Pharmacokinetic Study of TAK-438 in Healthy Adult Chinese Participants | Healthy Participants | P1 | Completed | 33 | Open-label | TAK-438 |
| NCT02723201 TAK-020 Relative Bioavailability and Food Effect Study in Healthy Participants | Healthy | P1 | Completed | 25 | RCT, Open-label | TAK-020 Captisol Oral Solution, TAK-020 CCT, TAK-020 SDT, TAK-020 IRT, TAK-020 CCT, TAK-020 Solid Formulation |
| NCT02906813 A Study to Determine the Bioavailability and Food Effect of a Single TAK-935 Dose in Healthy Participants | Healthy Volunteers | P1 | Completed | 9 | RCT, Open-label | TAK-935 Tablets, TAK-935 Oral Solution |
| NCT04833049 Study to Evaluate Absorption, Metabolism, and Excretion, of TAK-994 in 6 Healthy Male Adults | Healthy Volunteers | P1 | Completed | 6 | Open-label | TAK-994 Oral Tablet, [14C]TAK-994 Intravenous Infusion, [14C]TAK-994 Oral Suspension |
| NCT02442752 Phase 1 Dexlansoprazole Delayed-Release Capsules for Acid-Related Disorders in Infants Aged 1 to 11 Months | Pediatric Gastroesophageal Reflux Disease | P1 | Withdrawn | — | RCT, Open-label | Dexlansoprazole |
| NCT04745767 A Study of Different Forms of TAK-994 in Healthy Adults | Healthy Participants | P1 | Completed | 54 | RCT, Open-label | TAK-994, TAK-994, TAK-994, TAK-994, TAK-994 |
| NCT02327169 A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies | Advanced Nonhematologic Malignancies | P1 | Completed | 81 | Open-label | MLN2480, MLN0128, Alisertib, Paclitaxel, Cetuximab, Irinotecan |
| NCT03437564 A Bioequivalence Study of the Lu AA21004 20 mg and 2×10 mg Tablets | Healthy Adult Participants | P1 | Completed | 28 | RCT, Open-label | Vortioxetine |
| NCT02663687 Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Recombinant Human C1 Esterase Inhibitor in Healthy Adult Subjects | Hereditary Angioedema (HAE) | P1 | Completed | 48 | RCT, Double-blind | Recombinant human C1 esterase inhibitor, Placebo, SHP623, Placebo |
| NCT04964258 A Study of TAK-105 in Healthy Adults | Healthy Volunteers | P1 | Completed | 80 | RCT, Double-blind | TAK-105-a, TAK-105-a Placebo |
| NCT01898884 Safety and Pharmacology Study of VP 20629 in Adults With Friedreich's Ataxia | Friedreich's Ataxia | P1 | Completed | 46 | RCT, Double-blind | VP 20629, Placebo |
| NCT02367352 Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors | Advanced Solid Tumors, Ovarian Cancer | P1 | Terminated | 9 | Open-label | Alisertib, Paclitaxel |
| NCT03814005 A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems | Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic | P1 | Completed | 17 | Open-label | Azacitidine, Pevonedistat |
| NCT02728895 Dose Finding Study of Vedolizumab for GvHD in Participants Undergoing Allogeneic HSCT | Allogeneic Hematopoietic Stem Cell Transplantation | P1 | Completed | 24 | Open-label | Vedolizumab |
| NCT02716194 BAX 826 Dose-Escalation Safety Study | Hemophilia A | P1 | Completed | 40 | Open-label | BAX 826, Octocog alfa |
| NCT04460105 Lanadelumab in Participants Hospitalized With COVID-19 Pneumonia | COVID-19 Pneumonia | P1 | Withdrawn | — | RCT, Double-blind | Lanadelumab |
| NCT05025397 A Study of Danavorexton in Anesthetized Adults | Healthy Volunteers | P1 | Completed | 28 | RCT, Double-blind | Danavorexton, Danavorexton Placebo, Propofol, Sevoflurane, Propofol |
| NCT02541669 A Single- and Multiple-Dose Study of the Pharmacokinetics of TAK-491 in Healthy Chinese Participants | Healthy Volunteer | P1 | Completed | 64 | RCT, Double-blind | TAK-491, TAK-491 placebo |
| NCT05818956 A Study of TAK-227 in Healthy Adults | Healthy Volunteers | P1 | Completed | 24 | RCT, Open-label | TAK-227 |
| NCT01599819 BAX 855 Dose-Escalation Safety Study | Hemophilia A | P1 | Completed | 19 | Open-label | Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method, PEGylated Recombinant Factor VIII |
| NCT03401671 Study of Lanadelumab in Healthy Japanese and Matched Caucasian Adult Subjects | Healthy Volunteers | P1 | Completed | 32 | Open-label | Lanadelumab |
| NCT02123953 Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-438 in Healthy Male Participants | Dose Finding Study | P1 | Completed | 60 | RCT, Double-blind | TAK-438, TAK-438 Placebo |
| NCT04503603 A Study to Determine the Safety, Tolerability, and Pharmacokinetics of Lanadelumab Administered Intravenously in Healthy Adult Volunteer Participants | Healthy Volunteers | P1 | Completed | 12 | RCT, Double-blind | Lanadelumab |
| NCT00925704 The Pharmacokinetics of Rocaltrol When Administered Alone or in Combination With Fosrenol or Renvela in Healthy Volunteers | Healthy | P1 | Completed | 41 | RCT, Open-label | Calcitriol, Lanthanum carbonate + Calcitriol, Sevelamer carbonate + Calcitriol |
| NCT03849690 A Trial to Evaluate the Effect of the Proton Pump Inhibitor Esomeprazole on the Single-dose Pharmacokinetics (PK) of Oral TAK-906 in Healthy Adult Participants | Healthy Volunteers | P1 | Completed | 12 | Open-label | TAK-906, Esomeprazole |
| NCT02723006 Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma | Melanoma | P1 | Terminated | 22 | Open-label | TAK-580, TAK-202, vedolizumab, nivolumab, ipilimumab |
| NCT01716455 Study of SSP-004184 (FBS0701) in Healthy Adults and Elderly Subjects and in Subjects With Impaired Renal Function | Impaired Renal Function | P1 | Completed | 66 | RCT, Open-label | SSP-004184 |
| NCT04202497 A Study With [18F]MNI-1054 to Determine Lysine -Specific Demethylase 1A (LSD1) Brain Enzyme Occupancy of TAK-418 After Single-Dose Oral Administration in Healthy Participants | Healthy Volunteers | P1 | Terminated | 7 | Open-label | TAK-418, [18F]MNI-1054 (radiotracer) |
| NCT03801148 A Study to Compare the Bioavailability (BA) of Dexlansoprazole Delayed-release Capsules | Healthy Volunteers | P1 | Completed | 122 | RCT, Open-label | 30 mg dexlansoprazole capsules manufactured at TOB, 30 mg dexlansoprazole capsules manufactured at TPC, 60 mg dexlansoprazole capsules manufactured at TOB, 60 mg dexlansoprazole capsules manufactured at TPC |
| NCT06111547 A Study of TAK-279 in Healthy Chinese Adults | Healthy Volunteers | P1 | Completed | 24 | RCT, Double-blind | TAK-279, Placebo |
| NCT01191372 First-in-Human and Proof-of-Mechanism Study of ARC19499 Administered to Hemophilia Patients | Hemophilia | P1 | Terminated | 17 | RCT, Double-blind | placebo control, ARC19499 |
| NCT00962091 Study of MLN8237 in Participants With Advanced Solid Tumors | Advanced Solid Tumors | P1 | Completed | 53 | RCT, Open-label | Alisertib |
| NCT02942095 Study of Ixazomib and Erlotinib in Solid Tumors | Solid Tumors | P1 | Completed | 9 | Open-label | Ixazomib, Erlotinib |
| NCT00432510 Pharmacokinetics of C1 Esterase Inhibitor in Hereditary Angioedema Subjects | Hereditary Angioedema | P1 | Completed | 27 | RCT, Open-label | C1 esterase inhibitor [human] (C1INH-nf) |
| NCT00880750 Pharmacodynamic Study of Two Lanthanum Carbonate Formulations in Healthy Adults | End Stage Renal Disease | P1 | Completed | 72 | RCT, Open-label | Lanthanum carbonate Granule Formulation, Lanthanum carbonate Chewable Tablets (Fosrenol) |
| NCT06768658 A Study of TAK-951 in Participants With Cyclic Vomiting Syndrome (CVS) | Nausea and Vomitting | P1 | Terminated | 1 | RCT, Double-blind | TAK-951, TAK-951 Placebo |
| NCT06377228 A Study of TAK-007 in Adults With Refractory Lupus Nephritis (LN) or Refractory Systemic Sclerosis (SSc) | Refractory Lupus Nephritis, Refractory Systemic Sclerosis | P1 | Withdrawn | — | Open-label | TAK-007, Chemotherapy Agents |
| NCT02480439 A Study to Assess the Relative Bioavailability and to Assess the Effect of Food on the Bioavailability of a TAK-648 Tablet in Healthy Participants | Healthy Volunteers | P1 | Completed | 24 | RCT, Open-label | TAK-648 Tablet, TAK-648 Oral Solution |
| NCT01597401 A Single Dose Study of the Safety, Blood Levels and Biological Effects of Aes-103 Compared to Placebo in Subjects With Stable Sickle Cell Disease | Sickle Cell Disease | P1 | Completed | 19 | RCT, Double-blind | Aes-103, Aes-103, Aes-103, Aes-103, Placebo |
| NCT01078376 A Comparative Single-Dose Pharmacokinetic (PK) and Safety Study of Azilsartan Medoxomil in Children With Hypertension and in Healthy Adults | Hypertension | P1 | Terminated | 29 | Open-label | Azilsartan medoxomil (TAK-491), Azilsartan medoxomil (TAK-491), Azilsartan medoxomil (TAK-491), Azilsartan medoxomil (TAK-491) |
| NCT01454076 Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma | Nonhematologic Malignancies, Lymphoma | P1 | Completed | 112 | RCT, Open-label | Ixazomib 2.5 mg, Ixazomib 4 mg Capsule A, Ixazomib 4 mg Capsule B, Ketoconazole, Rifampin, Clarithromycin, Ixazomib 4 mg Capsule B |
| NCT02504320 Phase 1, Febuxostat XR Relative Bioavailability Study | Healthy Volunteers | P1 | Completed | 78 | RCT, Open-label | Febuxostat XR 80 mg Capsule F1, Febuxostat XR 80 mg Capsule F2, Febuxostat XR 80 mg Capsule F3, Febuxostat XR 80 mg Capsule F4 |
| NCT01387594 Evaluate PF-00547659 On Cerebrospinal Fluid Lymphocytes In Volunteers With Crohn's Disease Or Ulcerative Colitis Who Failed Or Did Not Tolerate Anti-TNFs | Crohn's Disease, Ileitis | P1 | Completed | 49 | Open-label | lumbar puncture |
| NCT04234672 A Study to Assess Absolute Bioavailability (ABA) of TAK-831 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]TAK-831 in Male Healthy Participants | Healthy Volunteers | P1 | Completed | 6 | Open-label | TAK-831 Oral Tablet, [14C]TAK-831 IV Infusion, [14C]TAK-831 Oral Suspension |
| NCT01318902 Study of Oral Ixazomib in Adult Participants With Relapsed or Refractory Light Chain Amyloidosis | Light-Chain Amyloidosis | P1 | Completed | 27 | Open-label | Ixazomib, Dexamethasone |
| NCT02528786 Blood Sample Collection Study for Pharmacogenomic Characterization of Participants That Previously Received Namilumab in M1-1188-002-EM (PRIORA, [NCT01317797]) Study | Rheumatoid Arthritis | P1 | Completed | 8 | Open-label | — |
| NCT03209258 The Third, Intensive Care Bundle With Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial | Cerebral Hemorrhage, Stroke | N/A | Completed | 7,067 | RCT, Single-blind | — |
| NCT05803200 A Study to Describe Mothers' and Babies' Outcomes After Exposure to HyQvia During Pregnancy | Exposure During Pregnancy | Completed | 7 | — | No intervention | |
| NCT03006965 Pharmacokinetic Characterization of the Hemophilia A Population in Spain Using myPKFiT® | Hemophilia A, Hemophilia | Completed | 50 | — | octocog alfa, rurioctocog alfa pegol | |
| NCT00745030 Efficacy and Tolerability of Ramelteon in Patients With Rapid Eye Movement (REM) Behavior Disorder and Parkinsonism | REM Behavior Disorder, Parkinsonism | N/A | Terminated | 3 | RCT, Double-blind | Rozerem, Placebo |
| NCT03433001 A Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated With Ixazomib Plus Lenalidomide and Dexamethasone | Relapsed and/or Refractory Multiple Myeloma | Completed | 295 | — | Ixazomib, Lenalidomide, Dexamethasone | |
| NCT01328392 Evaluating Treatment Response in Laryngo-Pharyngeal Reflux | Laryngo-pharyngeal Reflux | N/A | Withdrawn | — | Open-label | Dexlansoprazole |
| NCT04589039 A Study for Post-Marketing Surveillance of Niraparib in the Treatment of Adult Participants for Approved Indications in South Korea | Ovarian Neoplasms | Completed | 662 | — | — | |
| NCT00738725 BioImage Study: A Clinical Study of Burden of Atherosclerotic Disease in an At-Risk Population | Plaque, Atherosclerotic Disease | Completed | 7,687 | — | — | |
| NCT00919152 Economic Outcomes of Enteral and Parenteral Proton Pump Inhibitor (PPI) Use in the Intensive Care Unit (ICU) | Stress Ulcer Prophylaxis | Completed | 534 | — | — | |
| NCT02788916 A Retrospective Study of Clinical, Phenotypic and Genetic Factors of Peripheral T-Cell Lymphomas | Lymphoma, T-Cell, Peripheral | Completed | 198 | — | — | |
| NCT02139592 Brentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillance (All-case Surveillance) "Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma" | Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma | Completed | 292 | — | Brentuximab vedotin (recombinant) | |
| NCT04940611 A Study of Surgical Interventions in Fistulizing Conditions | Crohns Disease, Fistula | Completed | 646 | — | — | |
| NCT02106455 Sodium Risedronate Tablets - Special Drug Use Surveillance in Patients With Osseous Paget's Disease (All-case Surveillance) -48-week Surveillance - | Osseous Paget's Disease | Completed | 315 | — | Sodium risedronate | |
| NCT00706004 Short Term Safety and Efficacy of Lubiprostone in Adults With Cystic Fibrosis | Constipation, Cystic Fibrosis | N/A | Completed | 9 | Open-label | lubiprostone |
| NCT04501627 A Study on Vonoprazan in the Real-world Clinical Practice in China | Esophagitis Peptic | Completed | 3,000 | — | — | |
| NCT04002180 Specified Drug-Use Survey on Vedolizumab for IV Infusion 300 mg [Crohn's Disease] | Crohn's Disease | Completed | 335 | — | Vedolizumab (Genetical Recombination) | |
| NCT02454426 Vortioxetine in Patients With Major Depressive Disorder and Coronary Artery Disease | Major Depressive Disorder, Coronary Artery Disease | Early P1 | Withdrawn | — | Open-label | Vortioxetine |
| NCT04832087 Pediatric Teduglutide Registry | Short Bowel Syndrome | Completed | 142 | — | Teduglutide | |
| NCT02593188 Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA (Global) | Primary Immunodeficiency Diseases (PID) | Completed | 264 | — | HYQVIA | |
| NCT04721366 A Study of Velaglucerase Alfa (VPRIV) Given as Standard Patient Care in Young Children With Gaucher Disease | Gaucher Disease | Completed | 11 | — | — | |
| NCT04957641 A Study of the Burden of Illness and Treatment Patterns in Teenagers and Adults With Hereditary Angioedema | Hereditary Angioedema | Completed | 221 | — | — | |
| NCT00567502 Safety and Pregnancy Outcomes in Thrombocythemia Patients Exposed to XAGRID® (Anagrelide Hydrochloride) Compared to Other Treatments | Thrombocythemia, Essential | Completed | 3,647 | — | — | |
| NCT00611442 Split Dose Golytely With Amitiza Pretreatment Versus Split Dose Golytely Plus Placebo in Outpatient Colonoscopy | Bowel Preparation for Colonoscopy | N/A | Completed | 191 | RCT, Double-blind | lubiprostone, placebo |
| NCT03498625 Crohn's Disease Endoscopic REmission Definition in an Objective Way | CD | N/A | Completed | 240 | Open-label | — |
| NCT05384080 A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Poland | Inflammatory Bowel Disease (IBD), Crohn's Disease | Completed | 165 | — | — | |
| NCT00669461 Lubiprostone as a Treatment for Constipation in Parkinson's Disease | Constipation, Parkinson's Disease | N/A | Terminated | 1 | Open-label | Lubiprostone |
| NCT05107960 A Study of Azilsartan in Children From 6 to Less Than 16 Years Old With High Blood Pressure | Hypertension | Completed | 5 | — | Azilsartan (TAK-536) | |
| NCT01085643 Effect of Lubiprostone on Small Bowel Contractions in Female Patients With Constipation Irritable Bowel Syndrome (C-IBS) | Constipation-predominant Irritable Bowel Syndrome | N/A | Completed | 4 | Single-blind | Lubiprostone, Placebo |
| NCT04989907 A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Switzerland | Inflammatory Bowel Diseases, Crohns Disease | Completed | 92 | — | — | |
| NCT04876690 A Study of the Quality of Life in Adults With Crohn's Disease With Complex Perianal Fistulas | Crohn Disease, Rectal Fistula | Completed | 15 | — | — | |
| NCT03214198 Special Drug Use Surveillance of Vonoprazan for "Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Non-steroidal Anti-inflammatory Drugs: Long-term Use" | A History of Gastric or Duodenal Ulcers | Completed | 1,304 | — | Vonoprazan | |
| NCT01663207 Characterization of the Variability Of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Subjects With Prediabetes | Type 2 Diabetes | Completed | 20 | — | — | |
| NCT02002975 Pioglitazone Special Drug Use Surveillance "Metabolic Syndrome in Patients With Type 2 Diabetes Mellitus" | Type 2 Diabetes Mellitus | Completed | 18,223 | — | Pioglitazone | |
| NCT05770219 Expanded Access Program of TAK-755 for Congenital Thrombotic Thrombocytopenic Purpura (cTTP) | Thrombotic Thrombocytopenic Purpura (TTP) | APPROVED_FOR_MARKETING | — | — | TAK-755 | |
| NCT02958956 Cohort Study of Pioglitazone and Cancer Incidence in Participants With Diabetes Mellitus. | Diabetes Mellitus, Type 2, Cancer | Completed | 236,507 | — | Pioglitazone | |
| NCT02024971 Special Drug Use Surveillance of Pioglitazone/Metformin Hydrochloride Combination Tablets Survey on Long-term Use for Type 2 Diabetes Mellitus | Type 2 Diabetes Mellitus | Completed | 1,103 | — | Pioglitazone/metformin hydrochloride | |
| NCT03519672 Prospective Psychometric Evaluation Study of a Patient-reported Outcomes (PRO) Instrument for Congenital Thrombotic Thrombocytopenic Purpura (cTTP, Upshaw-Schulman Syndrome [USS], Hereditary Thrombotic Thrombocytopenic Purpura [hTTP] | Congenital Thrombotic Thrombocytopenic Purpura | Completed | 41 | — | — | |
| NCT05288491 A Study of Chinese Adults With Lymphoma | Lymphoma | Completed | 934 | — | — | |
| NCT03555591 Specified Drug-Use Survey of Trelagliptin Tablets "Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus" | Type 2 Diabetes Mellitus | Completed | 3,198 | — | Trelagliptin | |
| NCT01592136 Expanded Access Program of Ponatinib | Chronic Myeloid Leukemia (CML), Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) | APPROVED_FOR_MARKETING | — | — | ponatinib | |
| NCT00998244 Study to Evaluate the Effect of a Very Low Carbohydrate Diet on Gastroesophageal Reflux Disease | Gastroesophageal Reflux Disease, Overweight | N/A | Completed | 40 | RCT, Double-blind | — |
| NCT04057131 FIRAZYR General Drug Use-Results Survey (Japan) | Hereditary Angioedema (HAE) | Completed | 179 | — | Firazyr | |
| NCT05687474 Baby Detect : Genomic Newborn Screening | Congenital Adrenal Hyperplasia, Familial Hyperinsulinemic Hypoglycemia 1 | Completed | 6,824 | — | — | |
| NCT01350388 Effects of Febuxostat on Adipokines and Kidney Disease in Diabetic Chronic Kidney Disease | Chronic Kidney Disease, Diabetes | N/A | Completed | 80 | RCT, Double-blind | Febuxostat, Placebo |
| NCT03506386 Multiple Myeloma (MM) Profile in Brazil: A Retrospective Observational Analysis | Multiple Myeloma | Completed | 943 | — | — | |
| NCT02861118 A Retrospective Observational Study to Assess the Impact of Co-morbidities on Treatment Response in Inflammatory Bowel Disease | Inflammatory Bowel Disease | Completed | 310 | — | — | |
| NCT03942263 A Study to Describe Treatment Patterns and Disease Control in Participants With cHL and sALCL in Routine Clinical Practice in the Russian Federation | Hodgkin Disease, Lymphoma, Large-cell, Anaplastic | Completed | 2,000 | — | — | |
| NCT02674997 GAS-Hem Feasibility Study | Hemophilia A | Completed | 44 | — | Factor VIII | |
| NCT00613587 Roflumilast In-Vitro Basophil Release | Allergy, Asthma | Completed | 15 | — | — | |
| NCT04844593 A Study Using Artificial Intelligence to Identify Adults With Complex Perianal Fistulas Associated With Crohn's Disease | Crohn Disease, Rectal Fistula | Completed | 32 | — | — | |
| NCT03214952 Drug Use Surveillance of Vonoprazan for "Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis" | Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis | Completed | 3,183 | — | Vonoprazan | |
| NCT04535557 An Expanded Access Protocol for Mobocertinib in Refractory Non-small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Exon20 Insertion Mutations | Carcinoma, Non-Small-Cell Lung | APPROVED_FOR_MARKETING | — | — | Mobocertinib 160 mg | |
| NCT03242213 Patient Management of Depression Through Technology: a Study of Digitally Enabled Engagement | Major Depressive Disorder | N/A | Completed | 40 | RCT, Open-label | — |
| NCT04943796 A Study to Learn About the Occurrence of ADHD in Adults With Mental Conditions and Their Quality of Life | Attention Deficit Hyperactivity Disorder (ADHD) | Completed | 224 | — | — | |
| NCT01762501 Azilsartan Circadian and Sleep Pressure | Hypertension | N/A | Completed | 957 | RCT, Open-label | Azilsartan, Amlodipine |
| NCT00161720 Retrospective Study to Capture Dosing and Treatment Outcome Data in Participants With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND | Protein C Deficiency | Completed | 11 | — | Protein C Concentrate (Human) Vapor Heated | |
| NCT03214094 Special Drug Use Surveillance of Vonoprazan for "Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Low-dose Aspirin: Long-term Use" | Gastric or Duodenal Ulcers | Completed | 1,119 | — | Vonoprazan | |
| NCT01158911 Uric Acid and Long-term Outcomes in Chronic Kidney Disease | Chronic Kidney Disease | Completed | 838 | — | — | |
| NCT01194284 Surveillance Study of Patients With Newly Diagnosed Osteosarcoma | Osteosarcoma | Terminated | 25 | — | Mifamurtide | |
| NCT05686135 90Second IBD for the Improvement of Self Efficacy and Quality of Life in Inflammatory Bowel Disease Patients | IBD, Crohn Disease | N/A | Withdrawn | — | Open-label | — |
| NCT00689026 Efficacy of Lubiprostone in Combination With Standard PEG Preparation | Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | N/A | Terminated | 60 | RCT, Single-blind | Lubiprostone |
| NCT04980040 A Study for Post-Marketing Surveillance of Nesina® Tablet Monotherapy or Combination Therapy in Participants With Type 2 Diabetes (T2DM) in South Korea | Type 2 Diabetes Mellitus | Completed | 3,623 | — | Alogliptin Benzoate | |
| NCT01921075 Physiologic Plasticity of Intramyocardial Lipid Storage | Lipid Metabolism | Completed | 9 | — | — | |
| NCT04311541 A Study of Dexlansoprazole Modified Release (MR) in Gastroesophageal Reflux Disease (GERD) Participants in the Russian Federation | Gastroesophageal Reflux Disease | Withdrawn | — | — | — | |
| NCT02455024 An Observational Registry to Evaluate the Incidence of and Risk Factors for Vascular Occlusive Events Associated With ICLUSIG® | Myeloid Leukemia, Chronic-Phase, Accelerated-Phase, Blast-Phase, Ph+ALL | Terminated | 3 | — | — | |
| NCT05596422 A Study of Vedolizumab and Biologic Agents in Participants With Inflammatory Bowel Disease (IBD) | Inflammatory Bowel Disease (IBD), Ulcerative Colitis | Completed | 423 | — | — | |
| NCT03889613 Pillcam Crohn's Capsule for Monitoring of Panenteric Mucosal Healing in Crohn's Disease Patients With Vedolizumab | Crohn Disease | N/A | Unknown | 60 | Open-label | — |
| NCT01637935 Cohort Study of Pioglitazone and Bladder Cancer in Patients With Type II Diabetes | Diabetes, Bladder Cancer | Completed | 193,099 | — | Pioglitazone | |
| NCT04727476 The Use of Lisdexamfetamine for Children Aged 7-13 With Attention Deficit Disorders | Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder | Unknown | 413 | — | Lisdexamfetamine | |
| NCT04877431 A Study of Teduglutide (Revestive®) in Children, Teenagers and Adults With Short Bowel Disease | Short Bowel Syndrome | Completed | 45 | — | — | |
| NCT06062602 PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in HNSCC | Head and Neck Squamous Cell Carcinoma | Early P1 | Completed | 15 | Open-label | TAK-676, Carboplatin, 5-FU, Paclitaxel |
| NCT04998331 A Spanish Medical Record Review of Adults With Relapsed or Refractory CD30+ Malignancies When Re-treated With Brentuximab-vedotin | Hodgkin Disease, Lymphoma, T-Cell, Cutaneous | Completed | 51 | — | — | |
| NCT05371028 A Study of Teduglutide (Revestive®) in Participants With Short Bowel Syndrome (SBS) in Canada | Short Bowel Syndrome (SBS) | Completed | 52 | — | — | |
| NCT01661387 A European Post-Authorisation Observational Study (Registry) of Patients With Chronic Adrenal Insufficiency (AI) | Chronic Adrenal Insufficiency | Terminated | 3,258 | — | — | |
| NCT04883606 A Study With Teduglutide (Revestive®) in Adults With Short Bowl Syndrome | Short Bowel Syndrome | Completed | 65 | — | — | |
| NCT00619125 Proposal Evaluating Time-specific Relationships Between Variables of Pain, Stress, and Bloating in IBS Diarrhea and Constipation Symptoms Using a Palm Pilot | IBS, Diarrhea Predominant, IBS, Constipation Predominant | Completed | 85 | — | — | |
| NCT04941898 A Study of TAK-660 in Surgical Procedures for People With Hemophilia A. | Hemophilia A | Completed | 16 | — | PEGylated Recombinant Factor VIII | |
| NCT02170207 Takepron Intravenous 30 mg Specified Drug-use Survey [Acute Stress Ulcer and Acute Gastric Mucosal Lesions] | Acute Stress Ulcer and Acute Gastric Mucosal Lesions | Completed | 63 | — | Lansoprazole | |
| NCT06150534 At-Home Subcutaneous Immunoglobulin Replacement Therapy Using Alexa Skill | Primary Immunodeficiency Diseases (PID) | Completed | 22 | — | — | |
| NCT05073367 A Study Reviewing Medical Records of Adults With Helicobacter Pylori Infections in China | Helicobacter Pylori | Completed | 23,000 | — | — | |
| NCT03999567 Validation Study: Mobile DSST on Cognition in Adults With MDD | Major Depressive Episode | N/A | Completed | 30 | Open-label | — |
| NCT04213209 Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma" | Peripheral T Cell Lymphoma, Pediatric Hodgkin Lymphoma | Completed | 95 | — | Brentuximab Vedotin (Genetical Recombination) | |
| NCT04890262 A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in Real-World Practice | Inflammatory Bowel Diseases, Crohns Disease | Completed | 99 | — | — | |
| NCT03209479 Copaxone Subcutaneous Injection Syringe Special Drug Use-Result Investigation (All-Case Investigation) "Prevention of Relapse of Multiple Sclerosis" | Multiple Sclerosis | Completed | 1,332 | — | Glatiramer acetate | |
| NCT03214081 Special Drug Use Surveillance of Vonoprazan for "Maintenance Therapy of Reflux Esophagitis: Long-term Use" | Reflux Esophagitis | Completed | 1,237 | — | Vonoprazan | |
| NCT05886478 A Study in Adults With Cutaneous T-cell Lymphoma (CTCL) Retreated With Brentuximab Vedotin | T-Cell Lymphoma | Completed | 26 | — | No intervention | |
| NCT06433778 A Study on the Outcomes of Recombinant Von Willebrand Factor on Demand Treatment and Prevention and Treatment of Bleeding During and After Surgery in Adults With Inherited Von Willebrand Disease in the United Kingdom (UK) | Von Willebrand Disease (VWD) | Completed | 34 | — | — | |
| NCT01047306 A Study of Patients With Sanfilippo Syndrome Type A (MPS IIIA) | Sanfilippo Syndrome Type A | Completed | 25 | — | — | |
| NCT03555565 Specified Drug-Use Survey of Alogliptin and Metformin Hydrochloride Combination Tablets "Survey on Long-term Use in Type 2 Diabetes Mellitus Patients With Renal or Hepatic Impairment or Advanced Age" | Type 2 Diabetes Mellitus | Completed | 1,026 | — | Alogliptin and Metformin hydrochloride | |
| NCT01536457 Reflux Disease Therapy in the Management of Childhood Asthma-data Entry and Analysis Only | Asthma, Gastroesophageal Reflux Disease | Completed | 59 | — | — | |
| NCT03090139 Sub-optimal Response to Anti-Tumor Necrosis Factor's in Inflammatory Bowel Disease in Emerging Markets | Colitis, Ulcerative, Crohn Disease | Completed | 1,731 | — | Anti-TNF Therapy | |
| NCT01418781 CLinical Prediction Rule Score in Veterans | Gout | Withdrawn | — | — | — | |
| NCT05863026 Effectiveness of iDEAL in Improving the Knowledge, Attitude, Practice, Environmental Cleanliness Index and Dengue Index | Knowledge, Attitudes, Practice | N/A | Unknown | 1,600 | RCT, Single-blind | — |
| NCT02078427 ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD) | Hemophilia A | Completed | 951 | — | ADVATE, ADYNOVI | |
| NCT02099708 Long-term Use of Takepron on the Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Non-steroidal Anti-inflammatory Drugs | Gastric or Duodenal Ulcers | Completed | 3,502 | — | Lansoprazole | |
| NCT03681015 Wearable Assessments in the Clinic and Home in PD | Parkinson Disease | Completed | 132 | — | — | |
| NCT02986724 A Study to Observe the Safety and Efficacy of Vedolizumab in Biologically Naive Participants With Ulcerative Colitis (UC) or Crohn´s Disease (CD) | Crohn Disease, Colitis, Ulcerative | Completed | 60 | — | — | |
| NCT01034969 Firazyr® Patient Registry (Icatibant Outcome Survey - IOS) | Hereditary Angioedema (HAE) | Completed | 1,761 | — | — | |
| NCT05970159 Impact of Preoperative Serum Albumin Level on Postoperative Outcomes in Chinese HCC Patients Treated With Surgery | Hepatocellular Carcinoma | Unknown | 480 | — | — | |
| NCT01165190 Effect of Pioglitazone on Mitochondrial Function in Muscle and Adipose Tissue in Humans | Type II Diabetes Mellitus | Completed | 20 | — | — | |
| NCT02089997 Special Drug Use Surveillance on Long-term Use of Sodium Risedronate Tablets (Benet 75 mg Tablets) (12-month Treatment Survey) | Osteoporosis | Completed | 3,304 | — | Sodium Risedronate | |
| NCT01130831 Effect of Lanthanum Carbonate in Patients Previously Treated With Calcium-based Phosphate Binder Therapy | End Stage Renal Disease | Completed | 66 | — | Lanthanum carbonate |